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Since its inception in 1982, the Federal Circuit has declined to take
an overt role in setting patent policy. Dan Burk and Mark Lemley
have observed that the court instead implicitly engineers patent poli-
cy through selective application of its patentability rules, which
operate as "policy levers." Recent decisions on the patentability of
diagnostic and therapeutic methods illustrate a significant problem
with this approach. By maintaining a fagade of adjudicative rule
formalism while tacitly manipulating its rules to approximate policy
goals, the court perpetuates empirical uncertainty about the patent
law's practical effects.
This Article proposes that the Federal Circuit use the patentable sub-
ject matter doctrine as an explicit policy lever for calibrating patent
scope. By prompting litigants to directly address factual questions un-
derlying patent disputes, expressly pragmatic adjudication may serve
an information-eliciting function and shed light on longstanding theo-
retical debates. The Delaware Chancery Court's adjudication of
corporate law should serve as a model for the Federal Circuit's adju-
dication of patent law. This Article identifies queries specifically
pertinent to recent and ongoing cases involving medical methods and
suggests that the Federal Circuit raise similar empirical questions with
respect to software patents, business method patents, and other inven-
tions whose patentability is contested.
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INTRODUCTION
What is new in juristic thought today is chiefly the candor of its
processes. Much that was once unavowed and kept beneath the sur-
face is now avowed and open. From time immemorial lawyers have
felt the impulse to pare down the old rules when in conflict with the
present needs. The difference is that even when they yielded to the
impulse, it was their habit in greater measure than today to disguise
what they were doing, to disguise the innovation even from them-
selves, and to announce in all sincerity that it was all as it had been
before.I
This Article addresses two separate, but related, puzzles in patent law.
First, why do patent scholars widely disagree over how to allocate proprie-
tary rights to best achieve the patent system's utilitarian goals? Second, why
is the Federal Circuit so reluctant to openly mold patent law to meet the
needs of innovation policy?2 At first blush, these puzzles may seem unrelat-
ed. One puzzle exists in the theoretical patent literature while the other
manifests itself in the practice of patent adjudication. But the two puzzles
are very much connected, as they both stem from a lack of empirical data
about the patent system's specific practical effects. Rather than ignoring this
problem, the Federal Circuit should directly confront it. In so doing, the
court could help both to rationalize the patent doctrine and to inform
longstanding scholarly debates.
There is near universal agreement among courts and commentators that
the purpose of patent law is to further technological innovation.3 Despite
general accord on the patent system's utilitarian purpose, patent scholars
differ sharply over how best to fashion the law to achieve this goal.4 A num-
ber of insightful, well-reasoned, and markedly divergent approaches have
I. Benjamin Cardozo, Jurisprudence, in SELECTED WRITINGS OF BENJAMIN
CARDOZO: THE CHOICE OF TYCO BRAHE 7,37 (Margaret E. Hall, ed. 1947).
2. This is perplexing given the fact that the Federal Circuit is a specialist court with
the authority to shape the patent system, and the patent law is an unequivocally instrumentalist
legal regime. See infra Parts I-II.
3. Dan L. Burk & Mark A. Lemley, Policy Levers in Patent Law, 89 VA. L. REV.
1575, 1597-99 (2002); see also infra Part II.A.
4. See infra Part II.A.
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been advanced. One camp argues that patent exclusivity best encourages
research and development ("R&D"), while another asserts that competition,
not monopoly, best drives innovation.5 Some commentators advocate grant-
ing broad patent rights to upstream inventors, whereas others favor
allocating a larger portion of proprietary rights to downstream innovators. 6
While each approach depicts how patents operate with respect to some in-
dustries and technologies, the theoretical literature does not conclusively
identify the specific contexts in which each approach does or should prevail.
Indeed, academic patent scholarship reflects a "stalemate of empirical intui-
tions."'
Notably absent from this debate is the Federal Circuit.8 Congress creat-
ed the Federal Circuit as a specialist court with exclusive jurisdiction over
patent appeals in response to a perceived need to bring consistency to patent
law and to restore incentives for technological innovation.9 Since its incep-
tion in 1982, the court has adopted an approach to patent adjudication that
favors acontextual rules-based line drawing. The court has repeatedly es-
chewed taking a prominent role in patent policy engineering."o By many
accounts, the Federal Circuit has failed to produce the legal stability and uni-
formity that it was established to create." Moreover, the court has allowed the
5. Infra Part II.A.
6. Infra Part II.A.
7. ADRIAN VERMEULE, JUDGING UNDER UNCERTAINTY: AN INSTITUTIONAL THEORY
OF LEGAL INTERPRETATION 153 (2006) (observing a frequent "stalemate of empirical intui-
tions" in academic discussion where "the discovery that disagreements are empirical is often
taken to end the conversation").
8. Alan Devlin & Neel Sukhateme, Self-Realizing Inventions and the Utilitarian
Foundation of Patent Law, 51 WM. & MARY L. REV. 897, 901 (2009) ("A remarkable asym-
metry exists between the economic foundation of patent law and the doctrine that animates
this theoretical underpinning.").
9. S. REP. No. 275-97, at 5 (1981) ("The creation of the Court of Appeals for the
Federal Circuit will produce desirable uniformity in [patent] law."); THE UNITED STATES
COURT OF APPEALS FOR THE FEDERAL CIRCUIT: A HISTORY 1982-1990 12 (Marion T. Ben-
nett ed., 2002); Rochelle Cooper Dreyfuss, The Federal Circuit as an Institution: What Ought
We Expect?, 43 Loy. L.A. L. REv. 827 (2010) (noting that the Federal Circuit was established
for two main reasons: (1) to clear overcrowded dockets of the regional circuits by siphoning
off patent appeals; and (2) to introduce uniformity and stability into the patent law).
10. See infra notes 113-114 and accompanying text.
11. See, e.g., Jeffrey A. Lefstin, The Measure of the Doubt: Dissent, Indeterminacy,
and Interpretation at the Federal Circuit, 58 HASTINGS L.J. 1025, 1026 (2007) ("Commenta-
tors, practitioners, trial judges, and even some judges of the Federal Circuit themselves seem
united in their view that uncertainty and unpredictability are the order of the day."); Glynn S.
Lunney, Jr., Patent Law, the Federal Circuit, and the Supreme Court: A Quiet Revolution, I I
SUP. CT. EcoN. REV. L, 76 (2003) (asserting that empirical data "suggests that the Federal
Circuit and its doctrinal changes have brought less certainty and predictability to patent en-
forcement"); Craig Allen Nard & John F. Duffy, Rethinking Patent Law's Uniformity
Principle, 101 Nw. U. L. REV. 1619, 1621 (2007) ("The court's high rate of reversal of dis-
trict courts demonstrates that, despite the circuit's uniform national jurisdiction, 'the promises
of pre-trial predictability and expedient patent litigation seem to remain a tantalizing dream.' "
(citing Christian A. Chu, Empirical Analysis of the Federal Circuit's Claim Construction
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patent doctrine to become unmoored from the law's overarching utilitarian
purpose. In the last decade, the Supreme Court has granted certiorari in an
unprecedented number of Federal Circuit decisions.12 The Supreme Court's
uncharacteristic level of involvement in patent matters suggests that it too is
dissatisfied with the Federal Circuit's performance. 3
The Article proceeds as follows. Part I reviews the theoretical debate on
the optimal scope of patent protection for foundational discoveries that pave
the way for follow-on innovation. It shows how application of the patentable
subject matter ("PSM") doctrine and the enablement and written description
requirements (collectively, "the disclosure requirements") determines the
extent to which an upstream inventor may assert patent rights in after-arising
technologies. Part II summarizes and critiques the Federal Circuit's ap-
proach to questions of patent scope. Using recent opinions on the
patentability of medical methods as a case study, it shows that the core prob-
lem with the Federal Circuit's jurisprudence is its failure to openly
acknowledge the limitations of ex ante rules applied to varied, complex, and
shifting scientific and economic conditions.
Part III proposes a pragmatic adjudicative approach whereby the Feder-
al Circuit candidly acknowledges the fundamental empirical questions
underlying normative debates about patent scope. This Part explains why the
PSM doctrine is the best tool to explicitly calibrate patent rights. Finally, it
applies the proposed adjudicative model to recent and ongoing cases involv-
ing diagnostic and therapeutic methods. A brief Conclusion summarizes the
Article's main arguments.
Trends, 16 BERKELEY TECH. L.J. 1075, 1100 (2001))); Gideon Parchomovsky & R. Polk
Wagner, Patent Portfolios, 154 U. PA. L. REV. 1, 40-41 (2005) (noting "key areas of uncer-
tainty" in Federal Circuit doctrine, including claim construction, the doctrine of equivalents,
and the written description requirement); see also infra Part II.B.
12. Dreyfuss, supra note 11, at 829-30; see also In re Bilski, 130 S. Ct. 3218 (2010)
(patentable subject matter); Medimmune, Inc. v. Genentech, Inc., 549 U.S. 118 (2007) (stand-
ing to challenge a patent); KSR International Co. v. Teleflex Inc., 550 U.S. 398 (2007)
(nonobviousness); eBay Inc. v. MercExchange, L.L.C., 547 U.S. 388 (2006) (injunctive re-
lief); Merck KGaA v. Integra Lifesciences 1, Ltd., 545 U.S. 193 (2005) (statutory research
exemption); Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co., 535 U.S. 722 (2002)
(prosecution history estoppel).
1 3. Rochelle Cooper Dreyfuss, In Search of Institutional Identity: The Federal Circuit
Comes of Age, 23 BERKELEY TECH. L.J. 787 (2008); Rebecca S. Eisenberg, Commentary, The
Supreme Court and the Federal Circuit: Visitation and Custody of Patent Law, 106 MICH. L.
REV. FIRST IMPRESSIONs 28, 28 (2007), available at http://www.michiganlawreview.org/
firstimpressions/voll06/eisenberg.pdf ("The increasing propensity of the Supreme Court to
grant review in patent cases suggests that it is concerned about how good a job the Federal
Circuit is doing.").
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1. INTRACTABLE QUESTIONS OF PATENT SCOPE
A. The Theoretical Debate: "Stalemate of Empirical Intuitions"
Information possesses the classic characteristics of a public good-it is
both nonexcludable and nonrivalrous. 14 Consequently, absent patent protec-
tion, an inventor's inability to profit from her work might discourage her
from expending the time, money, and effort to create and disseminate her
invention. Intellectual property rights solve the public goods problem by
permitting prices to rise above marginal costs.' 5 Proprietary rights provide
both ex ante incentives to create and ex post incentives to develop and
commercialize inventions.16
Academic literature is in virtually unanimous consensus that patent law
exists to further utilitarian goals." The Supreme Court has repeatedly con-
firmed this utilitarian foundation," recognizing that patent law is a
14. See Mark A. Lemley, The Economics of Improvement in Intellectual Property Law,
75 TEx. L. REV. 989, 994 (1997) (stating that information is a quintessential public good,
because it can be consumed by many people without depletion; and once the creator makes it
publicly available, it is difficult to exclude those who use it without compensating the creator).
15. Id. at 996.
16. Mark A. Lemley, Ex Ante Versus Ex Post Justifications for Intellectual Property,
71 U. CHI. L. REV. 129, 131-32 (2004). For the argument that patent law's grant of property
rights facilitates commercialization by preventing others from free riding on the patentee's
investments in commercial testing, manufacturing, advertising, and distribution, see F. Scott
Kieff, Property Rights and Property Rules for Commercializing Inventions, 85 MINN. L. REV.
697, 710 (2001); see also F. Scott Kieff, Coordination, Property, and Intellectual Property:
An Unconventional Approach to Anticompetitive Effects and Downstream Access, 56 EMORY
L.J. 327, 333-34 (2006) (arguing that property rights enforced by strong property rules pro-
duce two beneficial effects: a "beacon" effect (multiple complementary users are drawn
together) and a "bargain" effect (such users are able to bargain more efficiently)). The late
Federal Circuit Judge Giles Rich advocated the commercialization theory of patents. See Giles
S. Rich, The Relation Between Patent Practice and the Anti-Monopoly Laws, 24 J. PAT. OFF.
Soc'Y 159, 177-81 (1942) (arguing that promoting the commercialization of inventions is the
most important function of patent law).
17. See, e.g., ROBERT P. MERGES & JANE C. GINSBURG, FOUNDATIONS OF INTELLEC-
TUAL PROPERTY 21 (2004) (noting that the "'utilitarian' view of intellectual property is
widely held to be the intellectual foundation for U.S. intellectual property law"); Burk & Lem-
ley, supra note 3, at 1597 ("While there have been a few theories of patent law based in moral
right, reward, or distributive justice, they are hard to take seriously as explanations for the
actual scope of patent law."); Devlin & Sukhateme, supra note 8, at 912 (concluding that the
utilitarian case for patent has proved "compelling"); Jonathan S. Masur, Regulating Patents,
2010 Sup. CT. REV. 275, 279 ("Economics plays as large a role in contemporary understand-
ings of the shape and scope of patent law as it does in nearly any other field.").
18. See, e.g., Diamond v. Chakrabarty, 447 U.S. 303, 307 (1980) ("The patent laws
promote this progress by offering inventors exclusive rights for a limited period as an incen-
tive for their inventiveness and research efforts." (quoting Kewanee Oil Co. v. Bicron Corp.,
416 U.S. 470, 480-81 (1974))); Aronson v. Quick Point Pencil Co., 440 U.S. 257, 262 (1979)
(citing Kewanee Oil, 416 U.S. at 480-81) (stating that the purposes of the patent system are
(1) to foster and reward invention; (2) to promote disclosure in order to stimulate new innova-
tion and to enable the public to practice the invention upon patent expiration; and (3) to assure
that the public can freely use ideas in the public domain); Graham v. John Deere Co., 383 U.S.
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government creation with a clear constitutional objective to "promote the
Progress of Science and useful Arts."'9 Ideally, exclusive rights should only
be granted if their social costs-restricted output, higher prices, and dynam-
ic inefficiencies-are outweighed by the benefits that accrue from
encouraging innovation, such that the patent grant results in a net increase in
social welfare.20 The desirability of patent protection is a function of both
the cost of R&D and the extent to which the inventor can appropriate returns
from her invention through means other than the patent system.2 A key de-
terminative factor is the ease with which a commercial product covered by
the patent can be imitated by competitors.22 In some cases, trademark and
trade secret protection may be sufficient to promote investment in innova-
tion despite the absence of a patent.23 In other circumstances, alternative
incentives may suffice. Ex ante incentives may include federal research
grants; ex post incentives may include prestige, promotion, tenure, 24 or the
opportunity to patent inventions further downstream in the product devel-
opment pipeline. Additionally, market-specific features such as first-mover
advantage and network effects may operate independently from the patent
system to shape inventors' motivations to innovate.25
Edmund Kitch's prospect theory of intellectual property posits that pio-
neering discoveries should receive expansive patent protection even if there
are non-patent incentives to create them.26 Prospect theory is premised on
two putative advantages of broad upstream patents: (1) they will induce
owners to invest in development without fear that competitors will appropri-
ate their work;27 and (2) they will allow owners to coordinate development
1, 8-9 (1966) ("[Thomas Jefferson] rejected a natural-rights theory in intellectual property
rights. The patent monopoly was not designed to secure to the inventor his natural right in his
discoveries. Rather, it was a reward, an inducement, to bring forth new knowledge.")
19. U.S. CONsT. art. I, § 8, cl. 8.
20. Devlin & Sukhateme, supra note 8, at 901 (noting that a patent can only be justified
on utilitarian grounds when it is necessary to incentivize the creation and dissemination of
inventions whose social value is greater than the associated deadweight loss).
21. Burk & Lemley, supra note 3, at 1586-87.
22. Id.
23. Michael W. Carroll, One Size Does Not Fit All: A Framework for Tailoring Intel-
lectual Property Rights, 70 OHIO ST. L. J. 1361, 1417 (2009).
24. See Burk & Lemley, supra note 3, at 1586-87 (delineating non-patent incentives to
innovate); Carroll, supra note 23, at 1409 (noting that in some cases nonpecuniary rewards
such as prestige and tenure may spur inventive efforts even in the absence of proprietary
rights); Henry E. Smith, Institutions and Indirectness in Intellectual Property, 157 U. PA. L.
REV. 2083 (2009) ("[T]he nonrival nature of information is a count against intellectual proper-
ty in comparison with rewards, kudos, lead times, and other alternatives to appropriating the
returns from inventive and other creative activity.").
25. Carroll, supra note 23, at 1414.
26. See Edmund W. Kitch, The Nature and Function of the Patent System, 20 J.L. &
EcoN. 265 (1977). Kitch's theory builds upon the work of economist Joseph Schumpter, who
argued that monopolists are best able to coordinate innovation. See JOSEPH SCHUMPTER, CAP-
ITALISM, SOCIALISM, AND DEMOCRACY 106 (6th ed. 1987).
27. Kitch, supra note 26, at 276-77.
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and avoid wasteful duplicative efforts by engaging in efficient licensing
transactions to bring innovative products to market. 28 The second of these
premises rests on Coasean assumptions of perfect information, perfect ra-
tionality, and minimal transaction costs. 29
The theory of competitive innovation developed by Kenneth Arrow ar-
gues against prospect theory by asserting that competition, not monopoly,
best spurs innovation. 30 On this view, patent rights should be narrowly con-
fined to specific embodiments of an invention and should not give the
patentee monopoly control over product markets. 31 Scholars have extended
this principle to incorporate the concept of cumulative innovation, in which a
final product is derived from a series of sequential steps by separate actors. 32
They challenge prospect theorists' presumption that rivalry is wastefully du-
plicative and assert that rights should be allocated between initial inventors
and subsequent improvers.33 Rejecting the notion that coordinated, central-
ized development by a single rights holder will give rise to a socially
optimal level of innovation, these scholars contend that a rational owner of a
broad upstream patent will typically underdevelop many of the potential
improvements subsumed by that patent. Moreover, they argue that coordi-
nated development may not be feasible where steep transaction costs are
associated with technology licensing.34
Other patent scholars have noted that such divided entitlements may
give rise to an anticommons whereby high transaction costs and strategic
behavior prevent the aggregation of the necessary rights to develop and
commercialize new products.3 1 Upstream inventors holding essential proper-
ty rights may hold up efforts by others to bring socially valuable
technologies to market. 36 Holdup problems may be significant in cases
28. Id. at 279.
29. Lemley, supra note 16, at 133. Compare John F. Duffy, Rethinking the Prospect
Theory of Patents, 71 U. CHI. L. REV. 439, 444, 475-80 (2004) (expanding on Kitch's theory
and noting that the earlier a patent is filed, the earlier the claimed invention enters the public
domain), with Michael Abramowicz, The Danger of Undeveloped Patent Prospects, 92 COR-
NELL L. REV. 1065, 1089 (2007) (critiquing Duffy's theory by noting that early filing
increases the likelihood that the patented technology will be underdeveloped).
30. Kenneth J. Arrow, Economic Welfare and the Allocation of Resources for Inven-
tion, in THE RATE AND DIRECTION OF INVENTIVE ACTIVITY 609 (Nat'l Bureau of Econ.
Research ed., 1962).
31. Id. at 619-20.
32. Burk & Lemley, supra note 3, at 1604-05.
33. See Robert P. Merges & Richard R. Nelson, On the Complex Economics of Patent
Scope, 90 COLum. L. REV. 839 (1990).
34. Id. at 876-79.
35. Id. at 872-75.
36. E.g., Michael A. Heller & Rebecca S. Eisenberg, Can Patents Deter Innovation?
The Anticommons in Biomedical Research, 280 SCI. 698 (1998) (identifying anticommons
problems in genomic research); Arti K. Rai, The Information Revolution Reaches Pharmaceu-
ticals: Balancing Innovation Incentives, Cost, and Access in the Post-Genomics Era, 2001 U.
ILL. L. REV. 173, 192-94 (asserting that upstream biotechnology patents could trigger bar-
gaining breakdown and impede innovation); see also Burk & Lemley, supra note 3, at 16t3
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where the subsequent improver's contribution to the resulting end product is
of significantly greater value than that of the initial inventor. If the parties
cannot expect to complete efficient transactions, broad upstream rights may
produce socially undesirable rent-dissipating patent races, as rational actors
overinvest in pioneering discoveries and underinvest in follow-on develop-
ment.38 Holdup concerns have prompted some scholars to advocate using
alternatives to intellectual property, such as rewards and prizes, to encourage
innovation.39 A related theory posits the problem of "patent thickets," in
which multiple broad patents are awarded to various parties laying claim to
the same technological ground.40 If transaction costs are too high to clear the
thicket via cross-licensing the overlapping rights, innovation can be imped-
ed. The patent thicket concept suggests that patent rights ought to be
sufficiently narrow to avoid the creation of overlapping rights. 4 1
An emerging area of scholarship goes beyond incentive theories42 by
recognizing the value of patents as tools to facilitate technology transfer.43
Academic writings incorporating a transaction cost economics ("TCE")
framework add a new dimension to the ongoing debate over the proper
scope of patent protection for upstream inventions. In addition to creating ex
ante and ex post incentives to innovate, patent rights can add value by fos-
(noting that there are two possible ways to solve anticommons problems: (1) grant fewer up-
stream patents or (2) consolidate patent property ownership via vertical integration).
37. See James Bessen, Holdup and Licensing of Cumulative Innovations with Private
Information, 82 EcON. LETTERS 321-26 (2004) (showing that ex ante licensing does not elim-
inate the holdup problem when follow-on innovators have private information about devel-
development costs); Lemley, supra note 14, at 1055-58 (noting that uncertainty over the value
of an upstream discovery and the threat of strategic behavior may prevent the inventor and
developer from agreeing to an efficient licensing transaction); Clarisa Long, Proprietary
Rights and Why Initial Allocations Matter, 49 EMORY L.J. 823, 831-36 (2000) (contending
that efficient licensing of basic research tools remains unattainable because of the uncertainty
in valuing patents).
38. Merges & Nelson, supra note 32, at 865-66; see also Robert Cooter, Stephen
Marks & Robert Mnookin, Bargaining in the Shadow of the Law: A Testable Model of Strate-
gic Behavior, II J. LEGAL STUD. 225, 226 (1982); Lemley, supra note 14, at 1064.
39. See, e.g., Michael Abramowicz, Perfecting Patent Prizes, 56 VAND. L. REV. 115
(2003). For application of the argument to the drug discovery context, see Joseph E. Stiglitz,
Scrooge and Intellectual Property Rights: A Medical Prize Fund Could Improve the Financ-
ing of Drug Innovations, 333 BRIT. MED. J. 1279 (2006); James Love & Tim Hubbard, The
Big Idea: Prizes to Stimulate R&D for New Medicines, 82 CHI.-KENT L. REv. 1519, 1528-34
(2007).
40. See Carl Shapiro, Navigating the Patent Thicket: Cross Licenses, Patent Pools, and
Standard Setting, in INNOVATION POLICY AND THE ECONOMY 119, 121 (Adam B. Jaffe et al.
eds., 2001).
41. Burk & Lemley, supra note 3, at 1614.
42. For a review of the patent literature on incentive theories and a collection of
sources, see DONALD S. CHISUM ET AL., PRINCIPLES OF PATENT LAW 58-90 (2d ed. 2001).
43. See Paul J. Heald, A Transaction Costs Theory of Patent Law, 66 OHIO ST. L.J. 473
(2005) (arguing that a patent regime lowers transaction costs relative to a trade secrecy re-
gime).
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tering collaborative relationships that might not otherwise form." Patents
make financing, long-term planning, and collaboration easier because prop-
erty rights-unlike contractual obligations-can be asserted against third
parties.4 5 Patent rights can also facilitate contracting by resolving the Arrow
Information Paradox.46 Furthermore, property rights can mitigate problems
of asset specificity and opportunism associated with collaborative agree-
ments.47 But when assessing the optimal scope of patent protection in any
given context, the benefits accruing from intellectual property rights must be
balanced against the costs of foreclosing some socially beneficial interac-
tions. 48
Despite substantial discussion and debate among practitioners and
scholars over optimal patent scope, data to confirm or refute the various pa-
tent theories remain elusive. For instance, few commentators contest the
notion that there is a causal link between patent rights, R&D investments,
and market productivity, but only scant empirical evidence supports this
fundamental assumption.49 A lack of comprehensive data on the economic
effects of patents makes it difficult to test divergent patent theories. This
information gap has created uncertainty about the patent system's optimal
form and operation.50 Problematically, both advocates and critics of strong
patent rights often rely on anecdotal evidence to support their positions. For
example, skeptics of prospect theory point to evidence of innovative stagna-
tion in the incandescent lighting field following the grant of an exceptionally
broad patent to Thomas Edison for his light bulb.' Several scholars have
44. Id.
45. Id.
46. Robert P. Merges, A Transactional View of Property Rights, 20 BERKELEY TECH.
L.J. 1477 (2005). Kenneth Arrow famously observed that the "fundamental paradox" of in-
formation is that "its value for the purchaser is not known until he has the information, but
then he has in effect acquired it without cost." KENNETH J. ARROW, ESSAYS IN THE THEORY
OF RISK-BEARING 152 (1971). Patent rights resolve this paradox by allowing owners to dis-
close proprietary information while retaining the right to be compensated for its use by others.
Merges, supra, at 1503.
47. Id.
48. Smith, supra note 24, at 2111-16.
49. Liza Vertinsky, Comparing Alternative Institutional Paths to Patent Reform, 61
ALA. L. REV. 501, 511 (2010).
50. See, e.g., Matthew Sag & Kurt Rohde, Patent Reform and Differential Impact, 8
MINN. J.L. Scl. & TECH. 1, 52 (2007) (noting the "empirical uncertainty surrounding optimal
patent scope"); Adam B. Jaffe, The U.S. Patent System in Transition: Policy Innovation and
the Innovation Process ii (Nat'1 Bureau of Econ. Research, Working Paper No. 7280, 1999)
("[DJespite ... the wide availability of detailed data relating to patenting, robust conclusions
regarding the empirical consequences for technological innovation of changes in patent policy
are few."); see also David McGowan, Copyright Nonconsequentialism, 69 Mo. L. REv. 1, 67-68
(2004) (delineating the argument, with respect to copyright law, that scholars lack the necessary
data to empirically measure the marginal effects of different policies).
51. Tim Wu, Intellectual Property, Innovation, and Decentralized Decisions, 92 VA. L.
REV. 123, 125-26 (2006).
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identified this problem and candidly admit that the theories they elucidate
and espouse await verification. 5 2
Without a clear idea about how well competing theories accurately de-
scribe and predict patent law's impact in the world, the academic debate
seems to have reached a "stalemate of empirical intuitions." 5 3
B. Patentability Requirements and After-Arising Technologies
Inventors need not actually reduce their inventions to practice in order
to obtain patent protection.5 4 Constructive reduction to practice suffices if
the description of the invention included in a filed patent application enables
the person having ordinary skill in the art ("PHOSITA") to practice the in-
vention.55 Patent claims may cover more than the specific embodiments
taught in the specification. 56 Each patent has a "footprint" that delineates the
extent to which a patent reaches back to claim modifications to previously
created technologies and reaches forward to claim embodiments yet to be
created.57 A patent may be objectionable because it seeks to cover too much
of the existing technological landscape, too many subsequent technologies,
or both. In other words, patentability must be assessed by reference both to
a claim's breadth (i.e., what is the range of currently foreseeable commercial
52. See, e.g., Kieff, supra note 16, at 411 n.291 ("Elimination of IP may not even be
bad; in fact, the commercialization theory would embrace a decision to eliminate IP if it
turned out that the commercialization benefits were outweighed by the costs of the system.
The analysis offered here suggests reasons why that is not expected to be the case. The ulti-
mate question, however is an empirical one and is not answered here." (emphasis added));
Brett M. Frischmann & Mark A. Lemley, Spillovers, 107 COLUM. L. REv. 257, 301 (2007)
("Spillovers aren't always bad, and more property rights aren't always good. Only if we un-
derstand when and why each can enhance social welfare can we hope to design legal rules that
do more good than harm."); Henry E. Smith, Intellectual Property as Property: Delineating
Entitlements in Information, 116 YALE L.J. 1742, 1818 (2007) ("The central empirical ques-
tion in both property and intellectual property is when-and how easily-to overcome the
basic presumption in favor of exclusion." (emphasis added)).
53. See VERMEULE, supra note 7; see also Cass R. Sunstein, Must Formalism Be De-
fended Empirically?, 66 U. CHI. L. REv. 636, 669 (1999) ("The broadest lesson has to do with
the relevance of empirical claims to many topics in legal theory, and the great difficulty of
doing the latter without attending to the former.").
54. Sean B. Seymore, Heightened Enablement in the Unpredictable Arts, 56 UCLA L.
REV. 127, 143-44 (2008).
55. Id.
56. Robin C. Feldman, The Inventor's Contribution, 2005 UCLA J.L. & TECH. 6, 160
("A patent holder need only identify a single use and a single embodiment for the product to
receive rights to a wide range of embodiments and all uses."); see also Rebecca S. Eisenberg,
Patents, Product Exclusivity, and Information Dissemination: How Law Directs Biopharma-
ceutical Research and Development, 72 FORDHAM L. REV. 477, 480 (2003) (noting that
patents track inventions, not product markets).
57. Robin Feldman, Rethinking Rights in Biospace, 79 S. CAL. L. REv. 1, 3 (2005).
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products that the patentee seeks to claim?) and to its depth (i.e., how far out
into the unforeseeable future does patent coverage extend?)."
The Patent Act delineates five main patentability requirements: (1) the
claimed invention must be eligible for patent protection; 9 it must possess
(2) utility,60 (3) novelty, 61 and (4) nonobviousness; 62 and (5) it must be sup-
ported by adequate disclosure. 63 Section 101 of the Patent Act states that
inventors may obtain patents for any "process, machine, manufacture, or
composition of matter, or any new and useful improvement thereof."" A
claim falling within one of these statutory categories may nonetheless be
patent-ineligible if it encompasses one of three judicially created exceptions:
products of nature, natural phenomena, and abstract ideas.65 However, the
useful application of fundamental principles towards specific ends may
qualify for patent protection.6 6 This doctrine of patentable subject matter
("PSM") thus performs two distinct functions: (1) it categorically excludes
certain types of discoveries; and (2) it limits the scope of patent claims. The
courts have construed Section 112's disclosure provision to contain two sep-
arate requirements: the specification must enable the PHOSITA to make and
use the invention (the enablement requirement), and it must adequately de-
scribe the invention to the PHOSITA to demonstrate that the patentee
possessed the invention at the time of application filing (the written descrip-
tion requirement).67 Although they are treated as distinct patentability
criteria, the disclosure requirements are conceptually linked both to each
58. See Kevin Emerson Collins, Enabling After-Arising Technology, 34 J. CORP. L.
1083, 1086 (2009) (stating that a claim's breadth describes the range of products encompassed
by the claim at the time of filing, while the claim's depth describes the expansion of the claim
set over time as claim scope reaches an increasing array of newly discovered after-arising
technologies).
59. 35 U.S.C. § 101 (2011).
60. Id.
61. Id. § 102.
62. Id. § 103.
63. Id. § 112.
64. Id. § 101.
65. Long-standing Supreme Court precedent holds that abstract ideas, scientific and
mathematical principles, and law or products of nature constitute unpatentable subject matter.
See Mayo Collaborative Servs. v. Prometheus Labs., 132 S. Ct. 1289, 1293 (2012); Diamond
v. Chakrabarty, 447 U.S. 303, 309 (1980) (citing Parker v. Flook, 437 U.S. 584 (1978));
Gottschalk v. Benson, 409 U.S. 63, 67 (1972); Funk Bros. Seed Co. v. Kalo Inoculant Co.,
333 U.S. 127, 130 (1948); Le Roy v. Tatham, 55 U.S. (14 How.) 156, 175 (1852).
66. See Mayo, 132 S. Ct. at 1293-94.
67. Dan L. Burk & Mark A. Lemley, Is Patent Law Technology-Specific?, 17 BERKE-
LEY TECH. L.J. 1155, 1174 (2002). Before 1997, the written description requirement was
generally thought to apply only to claims added after the original filing date, so as to prevent
the late claiming of new matter. However, in Regents of the University of California v. Eli
Lilly & Co., 119 F.3d 1559 (Fed. Cir. 1997), the Federal Circuit held that the written descrip-
tion requirement, like enablement, is applicable to all claims.
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other and to the PSM doctrine." Unlike the other patentability require-
ments,69 the enablement, written description, and PSM doctrines are
forward-looking-they address the proper scope of patent protection in light
of what potentially lies ahead. These three requirements operate prospec-
tively to restrict the reach of patent claims that seek to encompass future
embodiments. 70
The forward-looking patent doctrines grapple with the question of
whether the footprint of a patented invention should include after-arising
technologies that are unknown at the time the patent is filed. This question
confronts the "levels of abstraction" problem in the patent law.7' For exam-
ple, if an inventor devises a method of curing AIDS by means of a particular
machine, should she be able to claim all cures for AIDS that may ever be
discovered, only the specific method of curing AIDS through use of that
particular apparatus, or something in between?72 The level of abstraction at
which an inventor may obtain patent protection has significant consequences
for both the inventor's incentives and the rights of end users. The higher the
level of abstraction that may be claimed, the greater the incentive to invent
patentable technologies-but monopoly pricing will concurrently produce
deadweight losses as some potential users are priced out of the market. 3
Moreover, broad upstream patents may impede follow-on innovation by
discouraging others from creating after-arising technologies.7 1 In theory, the
permissible level of abstraction of a patent claim should correspond to the
inventor's contribution to the value of the commercial end products falling
under the claim's coverage.75 In reality, though, we often do not know and
cannot predict the inventor's proportionate contribution at the time the pa-
tent application is filed.
68. See Michael Risch, Everything is Patentable, 75 TENN. L. REV. 591, 598-606
(2008) (offering examples of PSM cases that could be reframed through the lens of other
patentability doctrines, such as novelty, utility, and adequate disclosure).
69. The utility requirement assesses the invention standing alone, without need to con-
sider related past, present or future technologies. The novelty and nonobviousness doctrines
operate retrospectively, comparing the claimed invention to the existing prior art to assess
patentability.
70. Collins, supra note 58, at 1086 (noting that the disclosure requirements are for-
ward-looking doctrines); Kevin Emerson Collins, An Initial Comment on Ariad: Written
Description and the Baseline of Patent Protection for After-Arising Technology, 2010 PA-
TENTLY-O PAT. L. J. 60, 64-65 (noting that the "abstract ideas" exception to PSM operates to
restrict the reach of patent claims into after-arising technology).
71. Tun-Jen Chiang, The Levels of Abstraction Problem in Patent Law, 105 Nw. U. L.
REV. 1097 (2011).
72. Id. at 1099-100.
73. See Dan L. Burk & Mark A. Lemley, Quantum Patent Mechanics, 9 LEWIS &
CLARK L. REv. 29, 51 (2005) (arguing that there is no right level of abstraction to apply to
claims when making infringement determinations).
74. See infra Part I.A.
75. Chiang, supra note 71, at 1104.
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An invention can be novel, useful, and nonobvious at multiple levels
of abstraction. Hence, these non-forward-looking patentability criteria
offer no guidance on the extent to which an upstream patent should read
on after-arising technologies.76 The work of resolving this problem must
be performed by the judicially created exceptions to PSM and/or the dis-
closure requirements.77 Unlike backward-looking determinations of patent
scope, which assess the invention by reference to the prior art-such as
novelty and nonobviousness-forward-looking patentability doctrines are
inherently indeterminate so long as inventors are allowed to claim more
than the specific embodiments disclosed in the specification. A key norma-
tive question underpinning both the PSM doctrine and the disclosure
requirements is: to what extent should the original inventor's patent read
on after-arising technologies? This is a difficult question to answer, as it
may be socially desirable to allow different inventions to be patented at
different levels of abstraction."
Forward-looking patent scope determinations are particularly thorny
when assessing the permissible bounds of method claims that are not cir-
cumscribed by a particular embodiment. The famous patent case involving
Samuel Morse's telegraphy patent is illustrative of this conundrum. 79 Claim
8 in Morse's patent application essentially claimed all methods of com-
municating at a distance using electromagnetic waves.80 But since Morse
had not disclosed, let alone envisioned, all such methods, the Supreme
Court ruled the claim invalid.8' The Court was concerned about impeding
future technological progress:
For aught that we now know, some future inventor, in the onward
march of science, may discover a mode of writing or printing at a
distance by means of the electric or galvanic current, without using
any part of the process or combination set forth in the plaintiff's
specification. . . . But yet if it is covered by this patent, the inventor
could not use it, nor the public have the benefit of it, without the
permission of the patentee... . In fine, [Morse] claims an exclusive
right to use a manner and process which he has not described and
76. Id. at 1133-34.
77. See John F. Duffy, Rules and Standards on the Forefront of Patentability, 51 Wm.
& MARY L. REV. 609, 645-46 (2009) (speculating as to why the prohibitions on undue ab-
straction and the patenting of natural phenomena are currently perceived as interpretations of
§ 101 when their "more obvious textual home" is § 112).
78. See Mark A. Lemley et al., Life After Bilski, 63 STAN. L. REV. 1315 (noting that
claims that are categorically excluded by § 101-claims that do not constitute a process, ma-
chine, manufacture, or composition of matter-are rare and can be dealt with fairly easily, and
that the more difficult cases are those involving claims that fall within one of the statutory
categories but nonetheless raise policy questions about whether they should be granted patent
protection).
79. O'Reilly v. Morse, 56 U.S. (15 How.) 62 (1854).
80. Id. at 112.
81. Id. at 119-20.
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indeed had not invented .... The court is of the opinion that the
claim is too broad, and not warranted by law.82
Although the Morse decision is considered by some to be a PSM case,83
the Court's opinion sounds very much like modem-day justifications for the
written description requirement. The conceptual link between the forward-
looking doctrines is further underscored by the fact that many commentators
view it as an enablement case.8 4
Contemporary disputes over the patentability of diagnostic and thera-
peutic methods raise analogous questions about an inventor's permissible
reach into after-arising technologies. These issues have come to the fore in
the wake of rapid scientific advances in biomedical research in recent dec-
ades. The discovery that a particular biological molecule correlates with a
particular condition or disease may spur the development of numerous
commercial products. For example, genetic discoveries can be used to de-
velop diagnostic tests that assess disease susceptibility, diagnostic tests that
tailor treatment options to a patient's unique genetic profile, and therapeu-
tics targeting genes or gene products implicated in disease pathways."
Questions of patent scope are of great importance to the biotechnology in-
dustry because unique biological molecules and processes cannot be readily
substituted by competitors in the same way that other components of pio-
neering inventions can.86
Product claims are broader than method claims in many cases. For ex-
ample, a product claim to a pharmaceutical compound covers all uses of the
compound and thus is broader than a method claim to a particular clinical
82. Id. at 113 (emphasis added).
83. Tun-Jen Chiang, The Rules and Standards of Patentable Subject-Matter, 2010 Wis.
L. REV. 1353, 1387 (noting that the Morse decision has generally been interpreted to establish
the principle that laws of nature and abstract ideas are not patentable); see also Peter S. Men-
ell, Forty Years of Wandering in the Wilderness and No Closer to the Promised Land: Bilski's
Superficial Textualism and the Missed Opportunity to Ground Patent Law Interpretation and
Return Patent Law to Its Technology Mooring, 63 STAN. L. REV. 1289 (2011) (stating that the
Supreme Court applied the "natural principles" exception to PSM in allowing Samuel F.B.
Morse's claims to specific uses of electromagnetism in telegraphy, but invalidating a broad
claim to the use of electro-magnetism "however developed for marking or printing intelligible
characters, signs, or letters, at any distances").
84. See, e.g., CRAIG ALLEN NARD, THE LAW OF PATENTs 51 (2007) (including Morse
in the section on enablement); Chiang, supra note 83, at 1396 (stating that the abstract ideas
doctrine is largely redundant with enablement and that Morse is often taught in law school
patent courses as an enablement case); Lemley et al., supra note 78, at 1332-33 (noting that
although Morse is generally regarded as an enablement case, the reasoning behind the Su-
preme Court's invalidation of Morse's eighth claim goes beyond the traditional concern about
enabling practitioners to make and use known embodiments without "undue experimenta-
tion").
85. Rochelle Dreyfuss, The Patentability of Genetic Diagnostics in U.S. Law and Poli-
cy 4-6 (N.Y.U. Sch. of Law Pub. Law & Legal Theory Research Paper Series, Working Paper
No. 10-68, 2010), available at http://ssrn.com/abstract= 1678123.
86. Id. at 8 (noting that it may not be easy to invent around broad medical method
claims because these inventions are "hostage to biology").
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use of that compound. But this observation does not necessarily hold for
upstream biotechnology patents that claim both a particular molecule (a
gene or protein) and the method of targeting that molecule. In this case, the
method claim may be of greatest value, because it captures a potentially
infinite range of therapeutic products." Claims to methods of targeting the
function of intracellular molecules or cell signaling pathways are much
broader than claims to methods of using a particular therapeutic product for
a particular clinical indication." While the latter type of therapeutic claim is
uncontroversial,"8 the patentability of the former is hotly contested.90
Diagnostic claims also raise difficult questions of permissible patent
scope.9' Claims to specific methods of assaying for a particular disease bi-
omarke 92 are undoubtedly patentable. However, the patentability of broad
claims to methods of correlating assay results with a condition or disease is a
subject of intense debate.93 The methods at issue in Laboratory Corporation
87. The parameters of a product claim are defined by the invention's structural charac-
teristics. A product generally cannot be claimed by reference to its function alone. The
USPTO will only allow product claims based on functional information if it is combined with
structural information about the product's genus. See Feldman, supra note 57, at 14. In con-
trast, there is no structural limitation imposed on claimed methods of targeting a gene or
biochemical pathway. See Collins, supra note 58, at 1105 (noting that "functional claim lan-
guage-at least when not construed as part of a means-plus-function limitation-often serves
as a red flag of a claim's potential depth").
88. The patents at issue in Eli Lilly & Co. v. Barr Laboratories, Inc., 251 F.3d 955
(Fed. Cir. 2001), exemplify the distinction between these two types of therapeutic claims. The
court held that the patent at issue, a method claim for blocking serotonin uptake, was antici-
pated by a prior Lilly method patent for treating anxiety with Prozac. Serotonin is a biological
compound implicated in anxiety and depression, and Prozac operates by inhibiting the cellular
reuptake of serotonin.
89. See Christopher M. Holman, Bilski: Assessing the Impact of a Newly Invigorated
Patent-Eligibility Doctrine on the Pharmaceutical Industry and the Future of Personalized
Medicine, 10 CURRENT Topics IN MEDICINAL CHEM. 1937 (2010) (noting that all biological
inventions implicate natural phenomena, but that drugs and methods of using drugs to treat
illness are undoubtedly patentable even though they typically interact with natural body pro-
cesses).
90. University of Rochester v. G.D. Searle & Co., 358 F.3d 916 (Fed. Cir. 2004) and
Ariad Pharms., Inc. v. Eli Lilly & Co., 598 F.3d 1336, 1366 (Fed. Cir. 2010) (en banc) are
prominent examples of disputes involving this type of therapeutic method claim. See infra
Parts Ill.B and IV.C.
91. Although the questions may be similar, the answers are potentially different. For
example, it may be optimal from a utilitarian perspective to allow patents covering therapeutic
methods at a higher level of abstraction than patents covering diagnostic methods. See infra
Part IV.C.
92. A biomarker is a protein or other substance that can be detected or measured in the
blood and whose concentration correlates with the risk or progression of a disease, or with a
patient's response to a given treatment. See Matthew Herder, Patents & The Progress of Per-
sonalized Medicine: Biomarkers Research as Lens, 18 ANNALS HEALTH L. 187 (2009)
(stating that biomarkers have a wide range of clinical applications, including disease preven-
tion, diagnosis, prognosis, prediction of therapeutic response, and measurement of therapeutic
efficacy and toxicity).
93. Recent high-profile cases considering the patentability of such methods include
Prometheus Laboratories, Inc. v. Mayo Collaborative Services, 628 F.3d 1347, 1354 (Fed.
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of America Holdings v. Metabolite Laboratories, Inc.94 (LabCorp) illustrate
the distinction between controversial and noncontroversial diagnostic
claims. Metabolite's patent contained narrow claims to a specific method of
assaying for homocysteine in a patient's blood, as well as broader claims to
correlating homocysteine levels with vitamin B deficiency. This broader
claim covered any diagnostic test developed to assess whether a patient has
a homocysteine level indicative of vitamin B deficiency. LabCorp undisput-
edly did not infringe the narrow claims to Metabolite's particular assay
methods, thus the resolution of the case turned on whether Metabolite's pa-
tent protection extended to the broad claim concerning the correlation
between homocysteine and vitamin deficiency.95
Until recently, courts relied primarily on the enablement and written de-
scription requirements to limit the reach of broad upstream claims.96 The
Supreme Court resurrected the PSM doctrine when it granted certiorari in
LabCorp. Although the Court ultimately dismissed the case as improvident-
ly granted,97 a vigorous dissent written by Justice Breyer (in which Justices
Stevens and Souter joined)98 alerted patent challengers to the potential for
using the PSM doctrine to cabin the scope of claims. 99 Patent scholars have
also taken a fresh look at the merits of using judicially created exceptions to
PSM as a means of allocating incentives between upstream inventors and
downstream developers.'" Nonetheless, the Federal Circuit seems reluctant
to adopt a more expansive approach to the PSM doctrine. In Bilski v. Kap-
pos,o'0 the Supreme Court overruled the Federal Circuit's determination that
PSM should be assessed by a sole, exclusive test which asks whether a
claimed method either (1) is tied to a particular machine or apparatus or (2)
transforms a particular article into a different state or thing (the "machine or
transformation" test or "MOT" test).'02 The Court concluded that the MOT
test was merely a "useful and important clue" to patentability, and that the
ultimate test for patentability is whether the claimed invention preempts all
Cir. 2010), and Ass'n for Molecular Pathology v. U.S. Patent & Trademark Office, 689 F.3d
1303, 1333-34 (Fed. Cir. 2012), cert. granted sub nom Ass'n for Molecular Pathology, 2012
LEXIS 9219 (U.S. Nov. 30, 2012) (No. 12-398).
94. Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc. (LabCorp), 548 U.S. 124
(2006) (per curiam).
95. Id. at 128-30 (Breyer, J., dissenting).
96. Holman, supra note 89, at 15 (stating that the PSM doctrine may be used to limit
patent scope, but that until recently, this function was accomplished by application of other
patentability doctrines, particularly the enablement and written description requirements).
97. LabCorp, 548 U.S. 124 (per curiam).
98. Id. at 125-39 (Breyer, J., dissenting).
99. Holman, supra note 89, at 10 (noting that the dissenting opinion in LabCorp
sparked renewed interest in the PSM doctrine).
100. See, e.g., Lemley et al., supra note 78, at 1315 (arguing that the abstract ideas ex-
ception to PSM should be used as a scope-defining doctrine).
101. Bilski v. Kappos, 130 S. Ct. 3218 (2010).
102. Id.
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uses of a fundamental principle.103 Despite the Supreme Court's ruling, the
Federal Circuit has continued to rely heavily on the MOT test to assess
PSM. 04
The Federal Circuit's insistence on limiting the PSM inquiry to the
MOT test reflects its general adherence to rules-based patent adjudication.
An open-ended query into whether a claim is invalid because it preempts all
uses of a fundamental principle does not yield readily predictable conclu-
sions. This is because the inquiry turns on how broadly the court defines the
fundamental principle at issue. For example, is the relevant fundamental
principle in LabCorp the general idea that blood homocysteine levels corre-
late with vitamin B6 deficiency or the more specific idea of assaying the
level of homocysteine in a patient's blood in order to diagnose vitamin B6
deficiency? The way in which the fundamental principle is articulated may
determine the outcome because a more broadly defined concept is less likely
to be found preempted than one that is more narrowly construed. The inher-
ent indeterminacy of the preemption inquiry may explain why the Federal
Circuit continues to latch on to the MOT test as the means for assessing
PSM.'0 The court understandably seeks to achieve stability and predictabil-
ity in the patent law through the use of bright-line rules. However, as
explained in Part II below, the Federal Circuit fails to acknowledge the limi-
tations of ex ante rulemaking under conditions of empirical uncertainty.
Instead, it perpetuates uncertainty and creates doctrinal confusion by main-
taining a fagade of adjudicative rule formalism while manipulating its rules
to produce intuitively desirable outcomes in specific cases.
103. Id. at 3221.
104. See, e.g., Prometheus Labs., Inc. v. Mayo Collaborative Servs., 628 F.3d 1347
(Fed. Cir. 2010) (noting, on remand, that the Supreme Court in Bilski did not invalidate the
MOT but merely held that it was not the definitive test for assessing preemption, and holding
that the asserted method claims constitute PSM because they satisfy the transformative prong
of the MOT test); King Pharms., Inc. v. Eon Labs, Inc., 616 F.3d 1267, 1278 (Fed. Cir. 2010)
("While the Supreme Court in Bilski made clear that our machine-or-transformation test is not
the exclusive test for patentability, it also made clear that the test is 'a useful and important
clue' . . . . We therefore understand the Supreme Court to have rejected the exclusive nature of
our test, but not necessarily the wisdom behind it.").
105. Timo Minssen & Robert M. Schwartz, US Patent Eligibility in the Wake of Bilski v.
Kappos: "Business as Usual" in an Age of New Technologies, 30 BIOTECH. L. REP. 3, 50
(2011) (observing that most determinations of patent eligibility for biotechnology inventions
will turn on the "natural phenomena" exception, but that the Supreme Court has offered very
little guidance as to what constitutes an unpatentable natural phenomenon).
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II. THE PITFALLS OF FEIGNED FORMALISM
A. Crystals or Mud in the Patent Law?
Patent scholars observe a propensity for formalism in the Federal Cir-
cuit's patent jurisprudence.'0 The court depicts patent law as an ordered
system founded upon a few abstract, discrete categories and higher princi-
ples.107 It perceives each of the statutory requirements as a distinct silo,
rigidly adhering to the notion that each substantive doctrine operates sepa-
rately and independently from the others. 1s The court also prefers the
certainty of rules over the indeterminacy of standards.'" Its approach is not
textual; it does not mechanistically apply statutory rules." 0 Rather, the Fed-
eral Circuit aims to develop its own judicially created rules with which to
apply vague statutory patentability criteria. A distinctive feature of formal-
ism is the notion that a legal rule is itself the reason for decision, rather than
the means for fulfilling an underlying social purpose."' The Federal Cir-
106. See, e.g., John R. Thomas, Formalism at the Federal Circuit, 52 AM. U. L. REV.
771, 773-74 (2003) ("Where the Federal Circuit once resolved issues based upon 'all the facts
and circumstances,' it now applies a discrete list of factors. Where the court once employed
standards, it now employs rules.. .. In short, the Federal Circuit has embraced an increasing-
ly formal jurisprudence.").
107. Lefstin, supra note 11, at 1044; see also VERMEULE, supra note 7, at 72 (explaining
that, in one sense of formalism, the adjudicator justifies the outcome by reference to concep-
tualist or essentialist reasoning and using as examples rulings on matters of constitutional law
based on distinctions between "manufacturing" and "commerce" or between "legislative" and
"executive" power).
108. See Collins, supra note 70 ("[PJatent litigation and scholarship are frequently con-
ducted within distinct doctrinal silos. Courts and manuscripts take on disclosure issues
(section 112, paragraph 1), functional claiming issues (section 112, paragraph 6), or utility
issues (section 101) in isolation, assuming that each doctrine maps onto a distinct normative
problem . . . ."); Lefstin, supra note I1, at 1044-47 (noting the Federal Circuit's formalist
conception of the patent system as a whole).
109. See Thomas, supra note 106, at 778-92 (offering five examples of the trend towards
adjudicative rule formalism in the Federal Circuit's patent jurisprudence: (1) the on-sale bar;
(2) the public dedication doctrine; (3) the "strict bar" approach to prosecution history estop-
pels as struck down by the Supreme Court in Festo Corp. v. Shoketsu Kinzoku Kogyo
Kabushiki, 535 U.S. 722 (2002); (4) the court's simple, permissive rule governing subject
matter eligibility set forth in State Street Bank v. Signature Financial Group, 149 F.3d 1368
(Fed. Cir. 1998); and (5) the court's teaching, suggestion, or motivation (TSM) test for nonob-
viousness); see also Arti K. Rai, Engaging Facts and Policy: A Multi-Institutional Approach to
Patent System Reform, 103 COLUM. L. REV. 1035, 1113-14 (2003) (arguing that the Federal
Circuit's Festo opinion suggests that adjudicative rule formalism and not simply pro-patent
bias drives the court's decisionmaking); see also Cass R. Sunstein & Adrian Vermeule, Inter-
pretation and Institutions, 101 MICH. L. REV. 885 (2003) (generally noting this sense of
formalism).
110. See Rai, supra note 109, at 1103 (noting the distinction between formalism and
textualism, and explaining that where a statute clearly adopts a standard, the formalist jurist
must go beyond the statutory text to craft a bright-line rule).
111. Frederick Schauer, Formalism, 97 YALE L.J. 509, 537 (1988) (explaining that in a
formalist decisionmaking process, "the rule itself becomes a reason for action, or a reason for
decision").
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cuit's MOT test exemplifies this aspect of formalism. The rule's narrow fo-
cus on physicality allows it to be applied without considering its purpose,
which is to limit the scope of patent protection for foundational discoveries
so as to encourage follow-on development."12
The Federal Circuit's preference for rules coincides with its clear disin-
clination to engage in explicit policy analysis." 3 While the court routinely
recites policy justifications for the statutory patentability requirements, it
rarely identifies policy reasons for its own decisions.1 4 The Federal Cir-
cuit's unwillingness to take an overt role in setting patent policy has sparked
a great deal of criticism from patent commentators, including former Chief
Judge Michel,"' who fear that the court's adherence to bright-line rules
might unmoor patent law from the goals of innovation policy."l Dan Burk
and Mark Lemley temper this charge by arguing that the court implicitly
112. See Bilski v. Kappos, 130 S. Ct. 3218, 3227-28 (2010) (noting that patentability
determinations involve "striking the balance between protecting inventors and not granting
monopolies over procedures that others would discover by independent, creative application
of general principles").
113. See, e.g., In re Fisher, 421 F.3d 1365, 1378 (Fed. Cir. 2005) ("[Piublic policy con-
siderations ... are more appropriately directed to Congress as the legislative branch of
government, rather than this court as a judicial body responsible simply for interpreting and
applying statutory law."); Alan D. Lourie, A View from the Court, 75 PAT. TRADEMARK &
COPYRIGHT J. 22 (2007) ("[N]ot once have we had a discussion as to what direction the law
should take .... We have just applied precedent as best we could determine it to the cases that
have come before us."); see also Dreyfuss, supra note 13, at 809 ("[T]he Federal Circuit tends
to favor a kind of formalism that is more characteristic of legal thinking in the nineteenth
century than in the twenty-first. Thus, opinions rarely provide insight into the goals the court
sees the law as achieving; 'policy discussions' take the form of incantations of standard justi-
fications of statutory terms."); Stuard Minor Benjamin & Arti K. Rai, Fixing Innovation
Policy: A Structural Perspective, 77 GEO. WASH. L. REv. 1, 18 (2008) (noting that the Federal
Circuit generally declines to engage in explicit policy analysis despite the patent statute's
open-ended language).
114. Dreyfuss, supra note 9, at 834. In the Federal Circuit's Bilski opinion, only Judge
Mayer, in dissent, explicitly considered the patent system's core utilitarian goals. See In re
Bilski, 545 F.3d 943, 1005-06 (Mayer, J., dissenting).
115. Nard & Duffy, supra note 11, at 1622 ("We just keep replicating the old results
based on the old precedents, whether they have kept pace with changes in business, changes in
technology, or changes of a different sort.") (citing Hon. Paul R. Michel, Chief Judge, U.S.
Court of Appeals for the Fed. Cir., Keynote Presentation, Berkeley Ctr. for Law & Tech. Con-
ference on Pat. Sys. Reform (Mar. 1, 2002)).
116. See, e.g., Devlin & Sukhateme, supra note 9, at 908 ("[The Federal Circuit opinion
in] Bilski, like the patentable subject matter cases that precede it, regrettably falls prey to a
judicial aversion to abstraction and ignores the incentive to invent and commercialize princi-
ples that motivate patent law."); Dreyfuss, supra note 13, at 803-04 (arguing that the Federal
Circuit's disinclination to explain the policy rationales driving its decisions makes it difficult
to discern when the court is taking the patent law in a new direction and gives rise to appeals
built around minute changes in the language of particular holdings); Rai, supra note 109, at
1037 (arguing that the Federal Circuit "adopt[s] bright-line rules that are insensitive both to
technological fact and to related issues of innovation policy"); Thomas, supra note 106, at
774-75 ("We can imagine a patent law as dynamic as the innovative industries it is said to
support, but an orientation towards rules threatens to make the patent law hidebound and unre-
sponsive to changing conditions.").
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directs patent policy through selective application of its patentability rules,
which operate as "policy levers."' 17 Their observation suggests that the Fed-
eral Circuit's approach is really one of feigned formalism. And as others
have noted, "once stripped of its formalist gloss," the Federal Circuit's
method actually encompasses a wide range of judicial discretion."' This
practice is socially desirable to the extent that it prevents absurd results that
would otherwise arise if the court actually adhered to strict formalism." 9
But feigned formalism is arguably worse than true formalism because it ne-
gates the key benefits that bright-line rules have to offer: predictability and
stability.120 It also belies the empirical uncertainty about patent law's practi-
cal effects that makes formulation and application of suitable patentability
rules so difficult. Rules work best when they possess three qualities: trans-
parency (the rule is easily understood); accessibility (the rule is easy to
apply to concrete situations); and congruence (the rule matches its underly-
ing policy objectives).121 The court's failing is its denial of the impossibility
of crafting ex ante patentability rules which simultaneously satisfy each of
these criteria in all cases. Rules may serve as useful guideposts, but they
cannot be exclusively relied upon to regulate complex, heterogeneous, and
constantly evolving technologies. By striving both to produce the certitude
of bright-line rules and to achieve intuitively appealing outcomes, the Fed-
eral Circuit ends up with the worst of both worlds: legal unpredictability and
a failure to mirror the patent system's utilitarian purpose in specific con-
texts. 122
Carol Rose famously observed that, in property law, we do not choose
between hard-edged rules ("crystals") and fuzzy, ambiguous ones ("mud").
Rather, we tend to oscillate between them.123 She notes:
The trouble, then, is that an attractively simple legal device draws
in too many users, or encourages too complex a set of uses. And
117. Burk & Lemley, supra note 3, at 1642.
118. Chiang, supra note 71, at 1123.
119. Id.at1124.
120. See Carl Tobias, The White Commission and the Federal Circuit, 10 CORNELL J.L.
& PuB. POL'Y 45, 58 (2000) (citing a 1999 report by the Commission on Structural Alterna-
tives for the Federal Courts of Appeals, which found that the Federal Circuit was second only
to the Ninth Circuit in the proportion of attorneys who concluded that the law of the circuit
was difficult to discern due to conflicting precedents); see also Thomas, supra note 106, at
796-97 (arguing that predictability and stability should not be the exclusive goals of the patent
law, and that, moreover, historical reflection on the Federal Circuit's decisionmaking casts
serious doubt on the notion that adjudicative rule formalism produces legal certainty).
121. Colin S. Diver, The Optimal Precision of Administrative Rules, 93 YALE L.J. 65, 67
(1983); see also Schauer, supra note 111, at 539 (explaining that rules cultivate predictability
only if the actors governed by the rule are able to easily identify how things will be catego-
rized and the actors' categorizations accord with the decisionmaker's categorizations).
122. For examples of this phenomenon, see infra Part I.B.
123. Carol M. Rose, Crystals and Mud in Property Law, 40 STAN. L. REV. 577, 593
(1988).
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that, of course, is where the simple rule becomes a booby trap. It is
this booby trap aspect of what seems to be clear, simple rules-the
scenario of disproportionate loss by some party-that seems to
drive us to muddy up crystal rules with the exceptions and the post
hoc discretionary judgments.124
The problem with the Federal Circuit's jurisprudence is that it obscures
the existence of an analogous phenomenon in the patent law." Examination
of the court's application of claim-construction canons, disclosure require-
ments, and the PSM doctrine reveals that the Federal Circuit depicts patent
law mud as if it were crystals.
Claim construction is ostensibly a textual exercise that leaves no room
for judicial discretion.126 Yet the Federal Circuit's conflicting canons of
claim construction have led to a wide variety of interpretative approaches.
While some courts construe claims broadly in accord with the literal lan-
guage of the claim and others construe claims narrowly to encompass only
the embodiment described in the specification, most courts adopt a middle
position whereby the construed scope of the claim extends beyond the spe-
cific embodiment but falls short of the level of abstraction embodied in the
plain meaning of the claim's language.'27 As one commentator notes: "Far
from creating a determinate and predictable system that secures patentee
rights free from the arbitrary whims of judges and [United States Patent and
Trademark Office ("USPTO")] bureaucrats, current claim construction ...
creates precisely the indeterminate free-for-all that formalism seeks to
avoid." 28
Similar pitfalls are apparent in the Federal Circuit's adjudication of the
disclosure requirements. One line of cases interprets the disclosure
provisions to require that the reader of the specification be able to construct
124. Id. at 597.
125. See Duffy, supra note 77, at 614 ("Eventually, rules always fail. This should sur-
prise no one who studies innovation. The unruly process of creative destruction has the power
to undermine today's legal rules every bit as much as it renders obsolete today's industrial
products, processes, and institutions.").
126. Chiang, supra note 71, at 1124-25.
127. Id. at 1109 (noting that uncertainty about claim construction "increases risk, en-
courages litigation, and disrupts business planning").
128. Id.; see also Ted Sichelman, Myths of (Un)Certainty at the Federal Circuit, 43
Loy. L.A. L. REV. 1161, 1191-92 (2010) ("[I]n its quest for predictability, the Federal Circuit
has adopted a number of 'canons' of claim construction, which-while seemingly instantiat-
ing a formal regime of transparent rules-are internally contradictory and rest on flawed
premises.... [I]t appears that typically unstated judicial ideologies influence judges, whether
conspicuous or not, to choose one of the competing canons in the cases in which they con-
flict."); see, e.g., Schering Corp. v. Amgen, Inc., 222 F.3d 1347 (Fed. Cir. 2000) (adopting a
strained interpretation of the claim-construction doctrine to limit the reach of the patentee's
claims to proteins, known as interferons, to the existing scientific knowledge at the time the
patent was filed).
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the full scope of the claim at the time of patent filing.129 Faithful
application of the full-scope rule denies the inventor the opportunity to
claim after-arising technologies.130 A second line of cases interprets the
disclosure requirements to say that the specification of a single embodiment
is sufficient (the "single-embodiment rule").131 Under this rule, a broad
claim is valid so long as the specification teaches the PHOSITA how to
make and use any one embodiment without undue experimentation.13 2
Faithful application of the single-embodiment rule allows the patentee to
reach into after-arising technologies and grants the patentee a claim of
indefinite temporal depth. Other enablement cases adopt a middle-ground
approach between the two extremes in requiring that there be a "reasonable
correlation" between the disclosure and the claims.133 Early Federal Circuit
decisions applied the single-embodiment rule to predictable (e.g., mechanical)
arts and applied the full-scope rule to unpredictable (e.g., chemical) arts. More
recent case law no longer predictably tracks this dichotomy.134
The Federal Circuit has inconsistently applied the disclosure require-
ments to biotechnology claims. For example, in Amgen Inc. v. Hoechst
Marion Roussel, Inc.,135 the court applied the single-embodiment rule to
uphold the validity of a broad claim to all "non-naturally occurring" forms
of the hormone erythropoietin ("EPO") based on the disclosure of one
method of making and using the claimed composition. This claim encom-
passed EPO created by after-arising scientific methods. On the other hand,
in Chiron Corp. v. Genentech Inc.,36 the court rejected the patentee's claim
to all monoclonal antibodies that bind to the human breast cancer antigen
Her2 based on an application that disclosed one such antibody. The court
concluded that claims to embodiments that do not exist in the art at the time
of the invention fail to satisfy the written description requirement. Lacking
clear guidance from the Federal Circuit with respect to the conflicts in the
law on disclosure, courts tend to manipulate the case law by selecting the
129. See, e.g., Liebel-Flarsheim Co. v. Medrad, Inc., 481 F.3d 1371, 1378-80 (Fed. Cir.
2007).
130. Taking the point even further, literal application of the full-scope rule threatens to
render worthless every patent in existence, because it allows competitors to avoid infringement
by incorporating into their products incremental technological changes that are developed after
patent filing. See Chiang, supra note 71, at 1114.
131. See, e.g., Invitrogen Corp. v. Clontech Labs., Inc., 429 F.3d 1052 (Fed. Cir. 2005).
In holding that the enablement requirement is met if the specification enables any mode of
making and using the invention, the court reasoned that, "[w]ere it otherwise, claim inventions
would not include improved modes of practicing those inventions. Such narrow patent rights
would rapidly become worthless as new modes of practicing the invention developed, and the
inventor would lose the benefit of the patent bargain." Id. at 107 1.
132. Collins, supra note 58, at 1088.
133. See, e.g., In re Vaeck, 947 F.2d 488, 495 (Fed. Cir. 1991).
134. Collins, supra note 58, at 1088.
135. Amgen Inc. v. Hoecht Marion Roussel, Inc., 314 F.3d 1313, 1329 (Fed. Cir. 2003).
136. Chiron Corp. v. Genentech, Inc., 363 F.3d 1247, 1255 (Fed. Cir. 2004).
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formalist rule that reaches the favored outcome in any given case.'37 The
Federal Circuit exacerbates doctrinal instability by denying any inconsisten-
cy in its application of the disclosure rules.' 3 .
Similar confusion abounds in the Federal Circuit's adjudication of the
PSM doctrine.' 39 The Federal Circuit and its predecessor court have rewrit-
ten the PSM doctrine multiple times in the past several decades.'40 When
one rule becomes unworkable, the court simply fashions a new rule that bet-
ter addresses changing conditions. But rather than admitting that a change in
the law is necessary, the court asserts that the newly articulated rule is what
the law really has been all along. In State Street Bank v. Signature Financial
Group,141 the Federal Circuit did not discuss the practical ramifications of its
decision to expansively define PSM as any invention that produces a "use-
ful, concrete, and tangible result." 4 2 The inadequacy of this permissive rule
ultimately compelled the court to replace it with the Bilski MOT test.143 yet
the MOT test seems destined to a similar fate. A patentability rule centered
on physicality is problematic in an era when many of our most important
technological advances-such as computer software and communications
technology-possess few if any physically transformative features.'"
B. Doctrinal Chaos: Medical Methods as Case Study
Medical method patents offer an illustrative case study of the problems
with the Federal Circuit's jurisprudence. Such patents impact an industry
characterized by cumulative innovation, a diverse array of market partici-
pants,145 and an elaborate regulatory framework that interacts with the patent
137. Collins, supra note 58, at 1088-89 ("[C]ourts exercise discretion . . . between the
full-scope and single-embodiment doctrines to achieve the desired outcome.").
138. See Automotive Techs. Int'l, Inc. v. BMW of N. Am., Inc., 501 F.3d 1274, 1281-
82 (Fed. Cir. 2007) (rejecting the argument that there is a "dichotomy in our case law").
139. See, e.g., Risch, supra note 68, at 591 (noting that PSM jurisprudence is "currently
confused and inconsistent").
140. Duffy, supra note 77, at 612 ("[T]he Federal Circuit and its predecessor court have
changed the rules governing patentable subject matter no less than three times in thirty
years."); see also id. at 639 (attributing the longevity of PSM's abstract ideas exception to the
fact that it is a malleable standard).
141. State St. Bank v. Signature Fin. Grp., 149 F.3d 1369 (Fed. Cir. 1998).
142. Id. at 1373-75.
143. In re Bilski, 546 F.3d 943 (Fed. Cir. 2008). See supra Part I.B.
144. Richard S. Gruner, In Search of the Undiscovered Country: The Challenge of De-
scribing Patentable Subject Matter, 23 SANTA CLARA COMPUTER & HIGH TECH. L.J. 395,
398 (2007).
145. See Alexander K. Haas, The Wellcome Trust's Disclosures of Gene Sequence Data
into the Public Domain & the Potential for Proprietary Rights in the Human Genome, 16
BERKELEY TECH. L.J. 145, 147 (2001) (explaining that the biomedical industry includes ge-
nomics companies, biotechnology companies, and traditional pharmaceutical companies); see
also Rebecca S. Eisenberg, Proprietary Rights and the Norms of Science in Biotechnology
Research, 97 YALE L.J. 177, 195 (1987) (noting that researchers within academia and industry
frequently collaborate with one another when working on similar problems).
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system to create a complex web of incentives to invent, develop, and com-
mercialize new technologies. 4 6 The Federal Circuit does not directly address
empirical uncertainty about the social desirability of broad upstream patents.
Instead, it seems to tacitly shunt its empirical intuitions into its application of
rules that are ostensibly only concerned with technological issues. The result
is an incoherent body of law that obscures questions about the practical ef-
fects of patenting biomedical discoveries.
The revived PSM doctrine offers the Federal Circuit a new tool to limit
the scope of medical method patents, since both diagnostic and therapeutic
claims implicate the "abstract ideas" and "natural phenomena" exceptions to
patentability.'4 7 Yet the court has thus far failed to clarify its application of
the MOT test to medical method claims. The en banc court deliberately
sidestepped the test in Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co.14 8 Ari-
ad held patents with broad claims to methods of targeting the intracellular
protein Nuclear Factor Kappa B ("NF-KB"), which scientists had implicated
in a variety of disease processes including cancer, AIDS, sepsis, and athero-
sclerosis. Prior to being sued by Ariad, Lilly had marketed and sold drugs to
treat osteoporosis and severe sepsis.149 At the time Lilly developed the com-
pounds, it did not know that those compounds acted at the molecular level
by inhibiting NF-iB activity.'15
The district court rejected Lilly's argument that claimed methods of re-
ducing intracellular NF- KB activity constituted unpatentable subject matter
and upheld the validity of the patent.' 5 ' The district court's decision turned
on a narrow, highly technical dispute over whether a natural process of in-
146. Benjamin & Rai, supra note 113, at 19-21 (explaining how FDA and NIH regula-
tions work in parallel with USPTO examination and Federal Circuit patent adjudication to
create incentives to create new drugs and biologics).
147. See Risch, supra note 68, at 627 ("A new use patent claims the natural phenomenon
that a medicine has a certain effect on the body (or, as in Metabolite, that certain test process
results reflect a certain condition), and the patentee is the first to discover the previously un-
known effect."); Eileen Kane, Patenting Genes and Genetic Methods: What's at Stake?, 6 J.
Bus. & TECH. LAW 1, 9 (2011) (noting that it is possible to imagine medical method claims
that would pass the MOT test but nonetheless preempt a natural phenomenon).
148. Ariad Pharms., Inc. v. Eli Lilly & Co., 598 F.3d 1336 (Fed. Cir. 2010) (en banc)
(reiterating that § 112 of the Patent Act contains a written description requirement that is sepa-
rate from the enablement requirement, affirming its holding that Ariad's patents were invalid
for failing to satisfy the written description requirement, and declining to address the question
of whether the claimed method constitutes PSM). This practice perpetuates the Federal Cir-
cuit's tendency to rely primarily on the disclosure requirements to limit the reach of
therapeutic method claims into after-arising technologies. See, e.g., Univ. of Rochester v.
G.D. Searle & Co., 358 F.3d 916 (Fed. Cir. 2004) (invalidating a patent claiming methods of
inhibiting COX-2 activity in a human host for failing to satisfy the written description re-
quirement where the patentees failed to identify a single compound that selectively inhibited
the COX-2 enzyme).
149. Ariad Pharms., Inc. v. Eli Lilly & Co., 529 F. Supp. 2d 106, 114 (D. Mass. 2007),
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hibiting NF-icB activity (an "autoregulatory loop") existed within cells. 152
Since Lilly failed to prove that the autoregulatory loop actually existed in
nature, the district court concluded that Ariad's patents did not cover a natu-
ral phenomenon.153 This conclusion begged the question: should the validity
of Ariad's patents hinge on the existence of a clinically insignificant auto-
regulatory loop? Perhaps recognizing the MOT test's deficiencies as applied
to medical methods, the Federal Circuit avoided the question of whether the
claimed methods constituted PSM.154 It concluded that the patent failed to
satisfy the written description requirement because the specification did not
disclose a sufficient number of species to receive patent protection for the
entire genus of claimed embodiments. Although the specification hypothe-
sized three classes of molecules capable of inhibiting NF-KB activity, this
disclosure was deemed insufficient to support broad claims to all means of
inhibiting NF-KB.15
The Federal Circuit bolstered its decision by reference to the patent sys-
tem's utilitarian purpose, but policy concerns hovered at the margins of the
court's analysis. The court observed: "Such claims merely recite a descrip-
tion of the problem to be solved while claiming all solutions to it .. . leaving
[the task] to the pharmaceutical industry to complete an unfinished inven-
tion."1 56 The opinion further noted: "Ariad presents no evidence of any
discernible impact on the pace of innovation or the number of patents ob-
tained by universities. But claims to research plans also impose costs on
downstream research, discouraging later invention."157 Yet the court failed to
articulate the legal relevance of such hypothetical evidence. If Ariad had
presented empirical data about the impact of broad therapeutic patents on
the incentives to discover and develop new drugs, how would that have af-
fected the Federal Circuit's analysis? What if Ariad had gone a bit further in
the development process and synthesized a molecule that demonstrated NF-
KB inhibition in vitro? Would it then have been entitled to the broad generic
claim that it sought? In refusing to directly confront the tension between
fostering ex ante incentives to create and sustaining ex post incentives to
develop, the Federal Circuit perpetuated uncertainty about the availability
152. Id. at 116-20.
153. Id.
154. Ariad Pharms., Inc. v. Eli Lilly & Co., 598 F.3d 1336 (Fed. Cir. 2010) (en banc)
(affirming its holding that Ariad's patents were invalid for failing to satisfy the written de-
scription requirement and declining to address the question of whether the claimed method
constitutes PSM).
155. Id. at 1349.
156. Id. at 1353; see also id. at 1349 (noting that the written description requirement
"keeps inventors from claiming beyond their inventions and thus encourages innovation in
new technological areas by preserving patent protection for actual inventions").
157. Id.
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and desirability of patent protection for broad upstream biological discover-
ies. 158
In its initial decision in Prometheus Labs, Inc. v. Mayo Collaborative
Services (Prometheus 1),159 the Federal Circuit applied the PSM doctrine but
characterized the disputed claims so as to minimize its effect. The court up-
held the validity of claims to methods of measuring the blood levels of
certain drug metabolites and using that data to optimize treatment of pa-
tients suffering from autoimmune diseases. Whereas the district court had
characterized the claims as describing correlations between metabolite lev-
els and therapeutic efficacy and toxicity,16 0 the Federal Circuit characterized
the claims as describing treatment methods.16' These divergent depictions of
the claimed methods flagged very different analytical approaches to their
patentability. The district court held them unpatentable for wholly preempt-
ing a natural phenomenon,'162 but the Federal Circuit reversed in finding that
they satisfied the MOT test.163 Notably, the Federal Circuit announced a
bright-line rule that treatment methods are "always transformative when a
defined group of drugs is administered to the body to ameliorate the effects
of an undesired condition.""
The Federal Circuit's Prometheus I decision was vacated and remanded
by the Supreme Court in light of the Court's holding in Bilski that the MOT
test is a useful, but nonexclusive, test for PSM.165 On remand, the Federal
Circuit reaffirmed its decision that Prometheus's asserted method claims are
drawn to PSM (Prometheus II).166 The court noted that the Supreme Court's
opinion in Bilski did not invalidate the MOT test, but merely held that it was
not a definitive test for assessing preemption of a natural phenomenon.167
158. Judge Newman wrote a separate concurring opinion "because the real issue of this
case is too important to be submerged in rhetoric." Id. at 1358 (Newman, J., concurring). She
urged the court to focus on overriding policy concerns rather than quibbling over which statu-
tory clause governs a particular case. Id. at 1359. Judge Rader wrote a separate opinion
dissenting-in-part and concurring-in-part with the majority. Rader rejected the majority's
conclusion that the Patent Act contains a separate written description requirement and strongly
criticized the decision as opening the floodgates for undisciplined judicial policymaking: "As
it stands, the court's inadequate description of its written description requirement acts as a
wildcard on which the court may rely when it faces a patent that it feels is unworthy of protec-
tion." Id. at 1366 (Rader, J., concurring in part, dissenting in part).
159. Prometheus Labs., Inc. v. Mayo Collaborative Servs. (Prometheus 1), 581 F.3d
1336 (Fed. Cir. 2009), vacated by 130 S. Ct. 3543 (2010).
160. Prometheus Labs., Inc. v. Mayo Collaborative Servs., No. 04cvl200 JAH (RBB),
2008 WL 878910, at *11 (S.D. Cal. Mar. 28, 2008).
161. Prometheus 1, 581 F.3d at 1343.
162. Prometheus Labs., 2008 WL 878910, at *12.
163. Prometheus 1, 581 F.3d at 1345-46.
164. Id. at 1346 (emphasis added).
165. Mayo Collaborative Servs. v. Prometheus Labs, Inc., 130 S.Ct. 3543 (2010)
(mem.).
166. Prometheus Labs., Inc. v. Mayo Collaborative Servs. (Prometheus II), 628 F.3d
1347 (Fed. Cir. 2010), rev'd, 132 S.Ct. 1289(2012).
167. Id. at 1355.
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The court reiterated its prior analysis that the asserted claims are effectively
treatment methods, satisfy the transformative prong of the MOT test, and
hence constitute PSM.168 The court thus seemed to pay lip service to the
Supreme Court's instruction in Bilski to create a more flexible PSM doctrine
by avoiding substantive changes to its articulated rules-based framework.
Dissatisfied with the Federal Circuit's resolution of the case, the Supreme
Court granted Mayo's petition for writ of certiorari and unanimously re-
versed the Federal Circuit's decision.' 69 The Court noted: "[I]n stating that
the 'machine-or-transformation' test is an 'important and useful clue' to
patentability, we have neither said nor implied that the test trumps the 'law
of nature' exclusion."' The Court also rejected the Government's sugges-
tion that any claimed method that minimally extends beyond a law of nature
itself should satisfy Section 101's PSM requirement.17 ' The Court highlight-
ed the underlying policy concerns, observing: "Patent protection is, after all,
a two-edged sword . . . patent law's general rules must govern inventive ac-
tivity in many different fields of human endeavor, with the result that the
practical effects of rules that reflect a general effort to balance these con-
siderations may differ from one field to another."72
In King Pharmaceuticals, Inc. v. Eon Labs, Inc.,1' the Federal Circuit
suggested that claimed methods of increasing the bioavailability of a muscle
relaxant by ingesting the drug with food are PSM. The court invalidated the
claims on other grounds but reiterated the notion that treatment claims nec-
essarily constitute PSM because they satisfy the transformative prong of the
MOT test.174 Yet the Federal Circuit took a strikingly different approach to
the treatment claims at issue in Classen Immunotherapies, Inc. v. Biogen
IDEC.' 5 The court affirmed a district court ruling that invalidated Classen's
patented methods for evaluating and improving the safety of immunization
schedules based on a discovered correlation between vaccines and chronic
immune-mediating disorders. In a terse unpublished opinion, the Federal
Circuit concluded that the methods constituted unpatentable subject matter
because they failed to satisfy the MOT test. The Supreme Court vacated the
168. Id. at 1355-56.
169. Mayo Collaborative Servs. v. Prometheus Labs., Inc., 132 S.Ct. 1289 (2012).
170. Id. at 1303.
171. Id. at 1303-04 ("[T]o shift the patent-eligibility inquiry to [sections 102, 103, and
112] risks creating significantly greater legal uncertainty, while assuming that those sections
can do the work that they are not equipped to do.").
172. Id. at 1305 (emphasis added).
173. King Pharms., Inc. v. Eon Labs, Inc., 616 F.3d 1267 (Fed. Cir. 2010).
174. Id. at 1278 ("We therefore understand the Supreme Court to have rejected the ex-
clusive nature of our test, but not necessarily the wisdom behind it .. . The present case,
however, does not present the proper vehicle for determining whether claims covering medi-
cal treatment are eligible for patenting under § 101 because even if claim 21 recites patent
eligible subject matter, that subject matter is anticipated [under § 102].").
175. Classen Immunotherapies, Inc. v. Biogen IDEC, 304 Fed. App'x 866 (Fed. Cir.
2008), rehg denied, 2009 U.S. App. LEXIS 24202 (Fed. Cir. 2009).
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Federal Circuit's Classen decision and remanded the case in light of its Bil-
ski opinion.17 6 On remand, the Federal Circuit held both that claims
including the transformative step of immunizing patients constituted PSM
and that claims merely describing utilizing published information to deter-
mine immunization schedules were not PSM."'
The Federal Circuit's divergent treatment of the claims in both of its
Prometheus holdings and Classen suggests that the court is crafting a new
implicit policy lever based on a distinction between significant and insignifi-
cant data gathering. Where the court aims to uphold the claims, as in the
Prometheus rulings, it concludes that the transformative aspects of the
claims. constitute significant data-gathering steps and thus satisfy the MOT
test. Conversely, where the court aims to invalidate the claims, as in Clas-
sen, the court concludes that the transformative aspects of the claims merely
constitute insignificant data-gathering steps and thus fail to satisfy the MOT
test. Rather than explicitly acknowledging its policy-laden judgments, the
court makes such determinations under the guise of a formalist rule.17 1 It
provides scant guidance as to how it will employ this new policy lever, ex-
acerbating current doctrinal confusion and unpredictability. Although the
Supreme Court, in its reversal of Prometheus II, cautioned against mecha-
nistic application of the MOT test,179 it nonetheless reaffirmed the test's
utility and signaled its approval of the Federal Circuit's focus on the distinc-
tion between significant and insignificant data-gathering activity.so Thus,
even after the reversal of Prometheus II, the Federal Circuit retains signifi-
cant discretion to operate this implicit policy lever.
The Federal Circuit chose to frame the complex claims in the Prome-
theus holdings as treatment methods and avoided directly answering the
difficult question of whether a claim to a medically significant scientific cor-
relation constitutes PSM. But the court was forced to address this issue in
Association for Molecular Pathology v. United States Patent Trademark Of-
fice (AMP).'8 ' The district court invalidated claims both to isolated and
purified BRCA1 and BRCA2 gene sequences and to methods of analyzing
those gene sequences to identify the presence of mutations correlating with
a predisposition to breast or ovarian cancer. The court came to this decision
176. Classen Immunotherapies, Inc. v. Biogen IDEC, 130 S. Ct. 3541 (2010) (mem.).
177. Classen Immunotherapies, Inc. v. Biogen IDEC, 659 F.3d 1057 (Fed. Cir. 2011).
178. For a discussion of other examples of implicit policy engineering and "feigned
formalism" in the Federal Circuit's patent jurisprudence, see supra, Parts I, II.
179. See Mayo Collaborative Servs. v. Prometheus Labs., 132 S. Ct. 1289, 1294 (2012)
(noting that Supreme Court precedents "wam us against interpreting patent statutes in ways
that make patent eligibility 'depend simply on the draftsman's art' without reference to the
'principles underlying the prohibition against patents for [natural laws]' ").
180. See id. at 1298 (reiterating its affirmation in Bilski of the principle that "the prohibi-
tion against patenting abstract ideas 'cannot be circumvented by' ... adding 'insignificant
post-solution activity' ").
181. Ass'n for Molecular Pathology v. U.S. Patent & Trademark Office (AMP), 653
F.3d 1329 (Fed. Cir. 2011), vacated, 467 Fed. App'x 890 (Fed. Cir. 2012).
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after concluding that the claims were unpatentable natural phenomena and
abstract mental processes. 18 2 Notably, although the district court's opinion
begins with an in-depth overview of the underlying policy concerns involved
in the dispute, 83 the holding that the methods claims are unpatentable is
grounded squarely on a formalist application of the MOT test.184 The deci-
sion never connects back to the practical implications of its ruling because
the district court lacks an adequate doctrinal hook to do so.
The Federal Circuit's treatment of the district court's ruling in AMP
perpetuated the disconnect between doctrine and policy. The court upheld
the composition of matter claims based on its semantic conclusion that an
isolated DNA molecule constitutes a distinct chemical entity unlike any-
thing found in nature because separation of a DNA sequence from its native
chromosome involves the breaking of a covalent chemical bond.'85 It invali-
dated the method claims to analyzing a patient's BRCAI and BRCA2 gene
sequences for cancer-predisposing mutations, concluding that the precise
wording of the claims failed to include transformative "administering" and
"determining" steps.'8 6 Thus, the holding implies that future patentees may
be able to obtain broad patent protection for diagnostic claims so long as
they carefully craft claim language to include transformative steps. Notably,
the court steadfastly adhered to the MOT test and declined to address policy
considerations.
The Supreme Court vacated the Federal Circuit's AMP decision and
remanded the case to the Federal Circuit for further consideration in light of
the Court's reversal of Prometheus II.m1 On remand, the Federal Circuit es-
sentially repeated its first decision by holding that Myriad's composition
claims to isolated gene sequences cover PSM and that Myriad's method
claims directed to comparing and analyzing DNA sequences are patent inel-
igible because they fail the MOT test. The court adhered to the MOT test in
reaffirming its determination that Myriad's method claims directed to screen-
ing potential cancer therapeutics are PSM. The Federal Circuit based this
decision on its observation that the claims involve the use of a man-made
182. Ass'n for Molecular Pathology v. U.S. Patent & Trademark Office, No. 09 Civ.
4515 (RWS), 2010 U.S. Dist. LEXIS 35418 (S.D.N.Y. Apr. 5,2010).
183. Id. at *53 (noting that the discovery of BRCAI resulted from research that was
supported heavily by federal funding); id. at *71-72 (citing Professors Heller and Eisenberg's
well-known article positing that gene patents deter biomedical R&D by creating a genetic
"anti-commons"); id. at *104 (quoting from Justice Breyer's dissent in LabCorp, in which
Breyer observed that "'sometimes too much patent protection can impede rather than 'pro-
mote the Progress of Science and useful Arts,' the constitutional objective of patent and
copyright protection' ").
184. Id. at*I49-58.
185. AMP, 653 F.3d at 1352-53.
186. Id. at 1356-57.
187. Ass'n for Molecular Pathology v. Myriad Genetics, Inc., 132 S. Ct. 1794 (2012)
(mem.).
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transformed cell and not natural material.' On September 25, 2012, the
American Civil Liberties Union filed a petition for writ of certiorari asking
the Supreme Court to again intervene in this case.'1 9 The Supreme Court
granted the petition on November 30, 2012, suggesting that the Court may
take further steps to compel the Federal Circuit to modify its PSM doc-
trine.190
Part III asserts that the Federal Circuit should cease implicitly engineer-
ing patent policy through haphazard application of the patentability
requirements and instead use the PSM doctrine as an explicit policy lever for
calibrating patent scope.
III. A PRAGMATIC PROPOSAL
A. Evidence-Based Patent Law
Patentability is often phrased as a query into whether an eligible inven-
tion is sufficiently novel, useful, nonobvious, and disclosed to deserve patent
protection. But if the driver of the patent system is social welfare, the central
inquiry should be what scope of patent protection (if any) is required to
promote the creation and development of the relevant technology.' 9' This
Part proposes expressly incorporating the principles of legal pragmatism
into patent adjudication. Although there is no universally accepted definition
of legal pragmatism, its core tenets include instrumentalism, contextualism,
and empiricism.192 Legal pragmatism is an offshoot of philosophical prag-
188. Ass'n for Molecular Pathology v. U.S. Patent & Trademark Office, 689 F.3d 1303,
1333-34 (Fed. Cir. 2012), cert. granted sub nom. Ass'n for Molecular Pathology, 2012 LEXIS
9219 (U.S. Nov. 30, 2012) (No. 12-398).
189. Petition for Writ of Certiorari, Ass'n for Molecular Pathology v. Myriad Genetics,
Inc., No. 12-398 (U.S. Sept. 25, 2012).
190. Ass'n for Molecular Pathology v. Myriad Genetics, Inc., No. 12-398 (U.S. Nov. 30,
2012).
191. See Dreyfuss, supra note 13, at 827 (asserting that, now that the Federal Circuit has
matured beyond experimental status and attained legitimacy, the Federal Circuit should shift
its focus from the short-term objectives of predictability and stability to the broader goal of
crafting the patent law to promote technological innovation).
192. See RICHARD A. POSNER, OVERCOMING LAW 19 (1995) ("Pragmatists want the law
to be more empirical, more realistic, more attuned to the needs of real people."); Richard A.
Posner, What Has Pragmatism to Offer Law?, 63 S. CAL. L. REV. 1653, 1657 (1990) ("The
thing that counts is that legal rules be understood in instrumental terms, implying contestabil-
ity, revisability, and mutability."); Thomas C. Grey, What Good Is Legal Pragmatism, in
PRAGMATISM IN LAW AND SOCIETY 9, 15 (Michael Brint & William Weaver eds., 1991)
("We pragmatists keep in the back of our minds the reminder that we are thinking to some
end-thinking instrumentally. We also keep there a reminder that we are thinking against a
background of tacit presupposition of which we can never be fully aware-thinking contextu-
ally."). Pragmatism has three main characteristics: hostility to metaphysical concepts (e.g.,
"nature") as objects of truth; insistence that propositions be assessed by their consequences;
and an emphasis on human need as a measure of the value of all social endeavors. Posner,
supra note 192, at 1660-61. Pragmatism is related to but distinct from legal realism, the
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matism, which advocates "an extension of the scientific method into all are-
as of inquiry."l 93
Legal pragmatism pervades the American judicial system.'94 It is odd,
therefore, that the Federal Circuit seems so reluctant to adopt a candidly
pragmatic approach to patent adjudication. In contrast to other substantive
areas, patent law is a nakedly instrumentalist creation whose uncontroverted
purpose is to promote technological innovation.'"9 As Judge Richard Posner
notes: "The more homogeneous, and therefore the wider the agreement on
what kind of consequences are good and what kind are bad (and how good
and how bad), the greater the guidance that pragmatism will provide." 96
Moreover, the patent system does not exist in a vacuum. The patent law op-
erates as part of a complex network of regulatory and incentive structures
that impose costs and bestow benefits on the creators, developers, and users
of innovative technologies.'97 Normative questions of patent scope thus nec-
essarily turn on "a pragmatic balancing of real-world consequences."'98
There is a solid historical basis for expressly pragmatic adjudication of
patent scope. The judicially created exceptions to PSM trace back to the
movement that emerged in the 1920s and 1930s as a response to the formalist legal thought
that dominated at the time. Realists rejected the notion that law is a comprehensive system of
autonomous conceptual propositions and emphasized its instrumental, practical, contextual,
and adaptive character. Pierre Schlag, Formalism and Realism in Ruins (Mapping the Logics
of Collapse), 95 IOWA L. REV. 195, 199 (2009). The tenets of early twentieth century realism
are present in modern day legal pragmatism and related schools of thought such as law and
economics, the legal process school, and critical thought. Id. at 207-08.
193. RICHARD A. POSNER, How JUDGES THINK 231 (2008) ("On a pragmatist view, our
ideas, principles, practices and institutions simply are tools for navigating a social and politi-
cal world that is shot through with indeterminacy."); see also id. at 233 (explaining that
philosophical and legal pragmatism are related but not identical, and noting that the "case for
legal pragmatism is based not on philosophical argument but on the needs and character of
American law").
194. See Brian Z. Tamanaha, How an Instrumental View of Law Corrodes the Rule of
Law, 56 DEPAUL L. REV. 469, 490 (2007) (noting that "U]udicial decisions today routinely
cite policy considerations, consider the purposes behind the law, and pay attention to law's
social consequences"); POSNER, supra note 193, at 230 ("The word that best describes the
average American judge at all levels of our judicial hierarchies and yields the greatest insight
into his behavior is 'pragmatist . . . .'). The tenets of pragmatism manifest themselves in the
teachings and decisions of Oliver Wendell Holmes. See, e.g., S. Pac. Co. v. Jensen, 244 U.S.
205, 221 (1917) (Holmes, J., dissenting) ("I recognize without hesitation that judges do and
must legislate."); OLIVER WENDELL HOLMES, THE COMMON LAW (1881) (announcing in the
first sentence that "[t]he life of the law has not been logic; it has been experience"); Oliver
Wendell Holmes, The Path of Law, 10 HARV. L. REV. 457 (1897).
195. See Masur, supra note 17, at 293-94 ("While contract and tort law may seek to
balance a variety of consequentialist and deontological considerations-welfare maximiza-
tion, efficiency, fairness, distributive justice, and so on-the objectives of patent law are
potentially more straightforward.").
196. POSNER, supra note 193, at 241.
197. Craig Allen Nard, Toward a Cautious Approach to Obeisance: The Role of Schol-
arship in Federal Circuit Patent Law Jurisprudence, 39 Hous. L. REV. 667, 668 (2002).
198. Chiang, supra note 83, at 1390.
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1852 Supreme Court opinion, Le Roy v. Tatham,199 in which the Court cited
concerns about the practical effects of overly broad patents.20 0 Similarly, the
legal framework for assessing nonobviousness set forth by the Supreme
Court in the 1966 case, Graham v. John Deere Co., 20t is "a legal question
sitting atop a highly fact-intensive contextual analysis." 202 The Federal Cir-
cuit has at least once applied this framework to explicitly incorporate R&D
costs into its nonobviousness analysis. 203 Another historical example of
pragmatic adjudication is the judicially created doctrine of equivalents,
which is intended to preserve the incentive structure of the patent system by
ensuring that competitors cannot easily escape liability by making insub-
stantial changes to their products.204 The Federal Circuit's preference for
bright-line rules has led it to essentially abandon this fact-dependent doc-
trine.205 But the time is ripe for the court to openly embrace pragmatism.
Justice Breyer's dissent in LabCorp,206 with Justices Stevens and Souter
199. Le Roy v. Tatham, 55 U.S. (14 How.) 156 (1852).
200. Id. at 174-75 ("A patent is not good for an effect, or the result of a certain process,
as that would prohibit all other persons from making the same thing by any means whatsoev-
er. This, by creating monopolies, would discourage arts and manufactures, against the avowed
policy of the patent laws.").
201. Graham v. John Deere Co., 383 U.S. 1 (1966).
202. Lee Petherbridge, On the Development of Patent Law, 43 Loy. L.A. L. REv. 893,
917 (2010); see also Robert P. Merges, Commercial Success and Patent Standards: Economic
Perspectives on Innovation, 76 CALIF. L. REv. 803, 815-16 (1988) (explaining that the Su-
preme Court supplemented a formalist three-part test for nonobviousness with a set of
contextual "secondary considerations" to formulate the modem nonobviousness standard, and
noting that the Court expressly "authorized courts to look at evidence outside the intrinsic
features of the invention and focus on the real world circumstances surrounding its origin and
commercialization").
203. See, e.g., Panduit Corp. v. Dennison Mfg. Co., 774 F.2d 1082, 1099 (Fed. Cir.
1985) (fact that patentee spent seven years and millions of dollars to create the invention is
evidence of nonobviousness).
204. See Wamer-Jenkinson v. Hilton Davis Chem. Co., 520 U.S. 17, 21 (1997) (explain-
ing that under the doctrine of equivalents, "a product or process that does not literally infringe
upon the express terms of a patent claim may nonetheless be found to infringe if there is
'equivalence' between the elements of the accused product or process and the claimed ele-
ments of the patented invention").
205. See Petherbridge, supra note 202, at 920-21.
206. Justice Breyer's pragmatic, evidence-based approach to intellectual property law
traces back to his seminal piece on the economics of copyright. See Stephen Breyer, The Un-
easy Case for Copyright: A Study of Copyright in Books, Photocopies, and Computer
Programs, 84 HARV. L. REV. 281 (1970) (making an argument against congressional expan-
sion of copyright law based on an analysis of the economics of the book publishing industry).
For an overview of Breyer's arguments in favor of pragmatic adjudication in general, see
Steven Breyer, Assoc. Justice, U.S. Supreme Court, Active Liberty: Interpreting Our Demo-
cratic Constitution, The Tanner Lectures on Human Values 68 (Nov. 17-19, 2004) (asserting
that pragmatic considerations should guide questions of statutory interpretation, but that judg-
es should not exercise unfettered discretion and must take account of "the legal precedents,
rules, standards, practices, and institutional understanding that a decision will affect").
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joining, 207 argued that overly expansive patent breadth might undermine
public health and scientific progress. 20 8 In Bilski, the Court cautioned that
patentability determinations should take into account economic factors, ap-
proving patents only where they will promote, rather than retard,
innovation.2" While not discarding the Federal Circuit's MOT test, the Su-
preme Court encouraged the Federal Circuit to articulate an adjudicative
framework that better reflects the patent system's overarching innovation
goals. 210
Pragmatism requires that the Federal Circuit, with the aid of sound con-
textual evidence, explicitly do what the courts have been doing implicitly (and
haphazardly) in their selective application of scope-defining patentability doc-
trines. The various patent theories delineated in the academic literature2"
present a set of hypotheses that should be tested empirically in specific con-
texts. 212 While rules such as the MOT test may offer a useful analytical
starting point, patentability should ultimately turn on straightforward ques-
tions about the disputed patent's impact on technological progress. The
Federal Circuit can encourage the aggregation and dissemination of the in-
formation needed to answer these questions by directly incorporating
evidentiary guideposts into its patentability determinations. Expressly
pragmatic adjudication can serve an information-eliciting function by creat-
ing an incentive for litigants to produce and interpret relevant empirical
information. Litigants are presumably rational actors, and will marshal
their resources and tailor their arguments according to the cues that they
are given in the Federal Circuit's opinions. If, as the court's recent hold-
ings seem to suggest, semantic arguments about an invention's physical
207. Although Justices Stevens and Souter have since retired, recent Supreme Court
decisions indicate that there is substantial support for pragmatic patent adjudication among the
current sitting justices.
208. Lab. Corp. of Am. Holdings v. Metabolite Labs, Inc.(LabCorp), 548 U.S. 124,
126-27 (2006) (asserting that the justification for excluding natural laws from patentable
subject matter "does not lie in any claim that . . . their discovery is easy, or that they are not
useful .. .. Rather, the reason for the exclusion is that sometimes too much patent protection
can impede rather than 'promote the Progress of Science and useful Arts', the constitutional
objective of patent and copyright protection"); see also Duffy, supra note 77, at 618 (noting
that Justice Breyer's LabCorp opinion implies that patentability determinations should not be
based on the social desirability of patents as ends in themselves, "but on empirical estimation
of the usefulness of patents in achieving other ends (progress)").
209. See Bilski v. Kappos, 130 S. Ct. 3218, 3228-29 (2010).
210. Id. at 3231 ("In disapproving an exclusive machine-or-transformation test, we by
no means foreclose the Federal Circuit's development of other limiting criteria that further the
purposes of the Patent Act and are not inconsistent with its text."); see also id. at 3253-57
(Stevens, J., concurring) (writing a separate opinion in which he relied on legal and economic
scholarship as well as "common sense" to conclude that business methods should be categori-
cally excluded from patentable subject matter).
211. See supra Part II.A.
212. See Richard A. Posner, Legal Pragmatism Defended, 71 U. CHi. L. REV. 683, 684
(2004) (explaining that legal pragmatism rejects decisionmaking based on abstract moral and
philosophical principles, but embraces theories that "guide empirical inquiry").
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nature are outcome-determinative, then litigants will devote their time and
energy to such issues. If, on the other hand, the court signals that the actual
economic impact of the contested patent is a central legal concern, then both
sides will be compelled to fill in gaps in the relevant empirical data.2 1'
The Federal Circuit's emphasis should be on increasing judicial can-
dor,214 asking the right factual questions, and acknowledging when answers
to those difficult questions remain unresolved. The court should refrain from
depicting patent mud as if it were crystals. 215 At the same time, it should
actively encourage the crystallization of some of the mud by identifying and
addressing areas of empirical uncertainty. Critics of pragmatic adjudication
argue that pragmatism has the potential to turn judges into "loose legislative
canons" and render the law hopelessly indeterminate. 216 But pragmatism's
call for increased judicial candor actually has the potential to curtail judicial
discretion. As Richard Posner notes: "Judges are less likely to be drunk with
power if they realize they are exercising discretion than if they think they
are just a transmission belt for decisions made elsewhere and so bear no
responsibility for any ugly consequences of those decisions." 2 17 A patent
213. See Nard & Duffy, supra note 115, at 1633 ("[T]he appellate system relies on the
argumentation of lawyers, and lawyers' arguments will be directly influenced by the appellate
structure and rules of circuit precedent."). It is preferable to directly encourage litigants to
generate and disseminate economic and empirical data, rather than to rely solely on amicus
briefs to offer contextual information. See Nard, supra note 197, at 686 (noting that, although
amicus briefs filed by third parties have the veneer of objectivity, amici writers may be moti-
vated to distort information to serve their own interests).
214. See Rochelle Cooper Dreyfuss, What the Federal Circuit Can Learn from the Su-
preme Court-and Vice Versa, 59 AM. U. L. REV. 787, 802 (2010) ("[T]he Federal Circuit has
to act like a teacher: it has to explain what policies it is adopting ... In other words, the Fed-
eral Circuit must articulate the theory on which it is relying."). For general arguments in favor
of judicial candor, see GulDo CALABRESI, A COMMON LAW FOR THE AGE OF STATUTES 178-
81 (1982) (discussing the benefits of judicial candor); Susan Estrich, The Justice of Candor,
74 TEx. L. REV. 1227, 1228 (1996) ("It is precisely because of its underlying political nature
that the task of judging ... demands both rigor and candor."); Scott C. Idleman, A Prudential
Theory of Judicial Candor, 73 TEx. L. REV. 1307, 1309 (1995) (arguing that it has traditional-
ly been recognized that "candor is an ideal toward which judges should almost always
aspire"); see also POSNER, supra note 193, at 271 (asserting that pragmatism is inescapable
and that denying it only has the effect of reducing judicial candor); Charles E. Clark & David
M. Trubek, The Creative Role of the Judge: Restraint and Freedom in the Common Law Tra-
dition, 71 YALE L.J. 255, 271 (1961) ("There should be a sterner and more forthright exercise
of judicial talent to look steadily and with balance to the consequences to be expected from
the judicial act and to its effect as a precedent on the growth of the law. Escape from this hard
task by reliance on neutrality and certainty to avoid forthrightness is itself a decision, albeit
one of negation.").
215. See supra Part II.A (discussing the distinction between mud and crystals as it re-
lates to patent jurisprudence).
216. POSNER, supra note 193, at 252.
217. Id. Federal Circuit Judge Plager has acknowledged that claim construction ultimate-
ly rests upon the court's contextual intuitions. See S. Jay Plager, The Federal Circuit as an
Institution: On Uncertainty and Policy Levers, 43 Lov. L.A. L. REV. 749, 761 (2010) ("How-
ever the judgments may be articulated, however rationalized they may be in terms of the
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doctrine that explicitly acknowledges the Federal Circuit's policy engineer-
ing role will prevent the court from washing its hands of any systemic
problems that its opinions engender.218
Ideally, patentability determinations should reflect a careful balance of
factors, including the need for patent-induced innovation, the competitive-
ness of the relevant market, the ease with which an invention's patentability
can be assessed, and the existence of mechanisms outside the patent law for
appropriating an invention's benefits. 2 19 The Federal Circuit should express-
ly incorporate contextual factors into its patent scope determinations. This
includes the cost of R&D, the ratio of R&D costs to imitation costs, techno-
logical risk, and the availability of non-patent alternatives for capturing the
social value of inventions. Alternative means of capturing value may include
government grants and other direct funding sources, non-patent legal means
of protecting proprietary rights (e.g., copyright, trademark, and trade secre-
cy), technical means of protecting information (e.g., encryption), and
market-based protections (e.g., first-mover advantage and network ef-
fects). 220
Importantly, as Judge Posner cautions, the Federal Circuit "must not
make the best the enemy of the good."221 Since the court will rarely have
information to reach the socially optimal result, its aim should be to reach
results that are "good enough" approximations. 222 The goal should not be to
ascertain optimal patent scope for every invention, but rather to accumulate
empirical information with which to move the patent law closer in that direc-
tion. Pragmatism's empirical focus favors an incremental approach, whereby
the Federal Circuit would decide difficult cases narrowly and then broaden the
reach of its decisions as knowledge accumulates. This approach would give
the court the flexibility to adapt the law to new information or changing cir-
cumstances without being unduly constrained by principles of stare decisis. 223
The pragmatic response to uncertainty about the consequences of ruling one
carefully selected canons of claim construction, the outcomes ... depend on the Federal Cir-
cuit's judgment about the sense of the situation.").
218. See supra Part tl.B (providing examples of doctrinal confusion stemming the Fed-
eral Circuit's sub rosa exercise of judicial discretion).
219. Thomas, supra note 106, at 799.
220. Peter S. Menell, A Method for Reforming the Patent System, 13 MICH. TELECOMM.
& TECH. L. REv. 487, 494 (2007).
221. POSNER, supra note 193, at 241; see also POSNER, supra note 192, at 396 (explain-
ing that the goal of legal pragmatism is not to attain some universal "truth" but rather to
constantly build upon our wealth of knowledge about the world).
222. POSNER, supra note 193, at 241. See also VERMEULE, supra note 7, at 176-78
(2006) (explaining that satisficing is a response to uncertainty in which a decisionmaker
searches for and selects the option that is "good enough" rather than holding out for the possi-
bility that maximizes welfare in the immediate case).
223. See POSNER, supra note 193, at 246-47 ("The broader the ground, the less scope the
judges will have for obtaining from future cases additional information bearing on the conse-
quences of the activity, because the decision will be a precedent that until overruled or
distinguished will rule new cases within its semantic domain, which may be vast.").
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way or another is to maintain the legal status quo.2 24 Therefore, an openly
pragmatic approach to a novel or difficult patentability case may be to point
out the relevant policy questions, to lament the paucity of available empiri-
cal data to definitively answer those questions, and to reluctantly follow the
most analogous precedent. The outcome in the immediate case might be the
same as that under a non-pragmatic regime, but such a real world-oriented
opinion would prompt litigants in future cases to produce and interpret rele-
vant data.22 1 Over time, the patent system as a whole would benefit from the
aggregation of contextual information with which to guide judicial deci-
sionmaking.
Expressly pragmatic patent adjudication could both enrich the case law
and move the academic community beyond its "stalemate of empirical intui-
tions" 226 by encouraging researchers not only to generate hypotheses but
also to test them empirically. With a few notable exceptions, 227 Federal Cir-
cuit judges have consciously refrained from referring to the academic patent
literature in their opinions. They defend this practice by asserting that schol-
ars' preoccupation with abstract modeling offers little practical guidance
about how to resolve specific cases.228 Although empirical research examin-
224. Richard A. Posner, Pragmatic Adjudication, 18 CARDOZO L. REV. 1, 8 (1996)
("[T]he effect of overruling [past decisions under conditions of uncertainty] would be to sacri-
fice certainty and stability for merely conjectural gain.").
225. This approach may help to mitigate the "repeat player disadvantage" identified by
Rochelle Cooper Dreyfuss. See Dreyfuss, supra note 214, at 805 (observing that a case of first
impression may set a precedent which, upon further reflection, is wrong, confusing, or ill-
suited to unforeseeable future situations, but that attorneys who appear before the Federal
Circuit regularly may be reluctant to take up the issue for fear of displeasing the judges and/or
tarnishing their reputations).
226. See supra Part l.A (discussing the argument that the academic patent literature
reflects a "stalemate of empirical intuitions").
227. Judge Newman has cited and discussed patent scholarship in several of her opin-
ions. See, e.g., Hilton Davis Chem. Co. v. Warner-Jenkinson Co., 62 F.3d 1512, 1529 (Fed.
Cir. 1995) (en banc) (Newman, J., concurring) (explaining how she has sought to understand
how the doctrine of equivalents affects technological innovation and stating, "This path has
led me into the thicket of the sociology and economics of patent law, for I have attempted to
place the basic question-the role and application of the doctrine of equivalents-into the
practical context of the purposes and workings of the patent system, as informed by modem
scholarship"), rev'd., 520 U.S. 17 (1997); see also Johnson & Johnston Assocs., v. R.E. Serv.
Co., 285 F.3d 1046, 1071-72 (Fed. Cir. 2002) (en banc) (Newman, J., dissenting) (discussing
economic and empirical literature).
228. See, e.g., Judge Michel Presses for More Data and Rigor in Patent Reform Pro-
cess, 63 PAT. TRADEMARK & COPYRIGHT J. (BNA) 429, 430 (Mar. 22, 2002) ("[W]hen the
court is asked to reconsider established patent law understandings, [Judge Michel] added, it
must rely on the briefs, and those filings rarely contain any 'data, facts, or hard numbers' to
substantiate the policy arguments being advocated by the litigants."); S. Jay Plager & Lynne
E. Pettigrew, Rethinking Patent Law's Uniformity Principle: A Response to Nard and Duffy,
101 Nw. U. L. REV. 1735, 1752 (2007) (criticizing patent scholars' suggestion that the Feder-
al Circuit engage the secondary patent literature, arguing that "to 'engage' the literature in an
opinion is an invitation to flights of dicta, that pervasive curse of the judicial process that adds
immeasurably to confusion in the law").
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ing the impact of patents on the innovation practices of firms does exist, 22 9
the bulk of academic patent scholarship is highly theoretical. 230 By signaling
the legal significance of empirical work, pragmatic patent adjudication may
thus create incentives for academics as well as litigants to focus on the pa-
tent system's specific practical effects. At the very least, an opinion citing
and discussing empirical and economic literature conveys to the affected
parties that the court appreciates the consequences of its decisions. Pragmat-
ic adjudication could also contribute to "the development of a pragmatic
culture-an environment where patent doctrine and policy can constantly be
subject to maintenance." 231
A pragmatic adjudicative regime need not be exclusively rules-based or
standards-based. 23 2 The Federal Circuit should stake out a middle ground
between the one extreme in which a court mechanistically applies rules
without regard to their underlying purposes, and the other extreme whereby
a court enjoys unfettered discretion to carry out the law's purposes as it sees
fit.233 The argument that a rule should remain tied to the reasons behind its
formulation does not lead to the conclusion that rules should be eliminated.
Well-crafted rules can help to quickly dispose of core cases and can serve as
229. See, e.g., Edwin Mansfield, Unauthorized Use of Intellectual Property: Effects on
Investment, Technology Transfer, and Innovation, in GLOBAL DIMENSIONS OF INTELLECTUAL
PROPERTY RIGHTS IN SCIENCE AND TECHNOLOGY 107 (Mitchel B. Wallerstein et a]. eds.,
1993) (surveying 100 American firms about the importance of intellectual property rights in
relation to direct foreign investment); Wesley M. Cohen et al., Protecting Their Intellectual
Assets: Appropriability Conditions and Why U.S. Manufacturing Firms Patent (or Not) 4
(Nat'l Bureau of Econ. Research, Working Paper No. 7552, 2000) ("Other reasons for patent-
ing-found to vary by industry-include blocking rivals from patenting related inventions . . .
and using patents in negotiations over technology rights."); Richard C. Levin et al., Appropri-
ating the Returns from Industrial Research and Development, 3 BROOKINGS PAPERS ON EcON.
ACTIVITY 783, 793-95 (1987) (analyzing 650 responses to a questionnaire about the effec-
tiveness of alternative means of protecting new inventions).
230. See Carroll, supra note 23, at 1434 ("Subsequent economic analysis of intellectual
property law has largely eschewed evidence-based analysis for more abstract modeling."); see
also Schlag, supra note 192, at 216 (observing academics' general tendency towards abstrac-
tion and stating, "In a powerful (and not fully explained) sense, comprehensive formalism
remains, for many legal academics, a kind of closet ideal. All this theorizing, modeling, and
paradigm-building; all this highly conceptualist work; and all this automatic insistence on
elegance, coherence, systematicity, and precision regardless of context suggest the continued
hold of the formalist ideal on the American legal-academic imagination").
231. Nard, supra note 197, at 685.
232. See Posner, supra note 224, at 16 (noting that pragmatism is "wholly neutral" on
whether to apply the law by rules or by standards). For a general overview of the rules versus
standards debate, see Louis Kaplow, Rules Versus Standards: An Economic Analysis, 42
DUKE L.J. 557 (1992); Colin S. Diver, The Optimal Precision of Administrative Rules, 93
YALE L.J. 65 (1983); Peter H. Schuck, Legal Complexity: Some Causes, Consequences, and
Cures, 42 DUKE L.J. I (1992).
233. See Lawrence A. Cunningham, A Prescription to Retire the Rhetoric of "Princi-
ples-Based Systems" in Corporate Law, Securities Regulation, and Accounting, 60 VAND. L.
REV. 1409, 1413 (2007) (noting that regimes governing corporate law, securities regulation,
and accounting systems exist on a continuum on the rules/principles axis and cannot be neatly
placed into either category).
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useful illustrative, but not dispositive, guideposts for difficult boundary cas-
es. 2 34 Patent adjudication may work best under a system of "presumptive
formalism" in which the applicable precedential rule would presumptively
govern, but could be rejected if the particular facts of the case suggest that
its application would contravene the purpose behind the rule.235 Indeed, the
Supreme Court seemed to instruct the Federal Circuit to adopt this type of
approach in its Bilski opinion. The Court did not strike down the MOT test
but cautioned the Federal Circuit to apply it as a rule of thumb rather than as
a mechanistic exclusive test.236
While it may be pragmatic for the Federal Circuit to continue to rely on
precedential rules when dealing with cases of first impression, it should be
willing to discard or revise those rules as new information develops. 237 The
patentability of DNA sequences offers an illustrative case in point. Under cur-
rent guidelines, human genes may be patented so long as the invention
describes a gene that has been isolated and purified from its natural setting.2 38
This rule traces back to Judge Learned Hand's 1911 decision in Parke-Davis
& Co. v. H.K. Mulford Co., 239 which upheld a patent on adrenaline that had
been purified from the adrenal glands of cadavers because-unlike adrenaline
in its natural setting-the patented substance had practical therapeutic utility.
By signaling its approval of a formalist rule that all useful biological inven-
tions are PSM so long as they are altered from their natural state, the Federal
Circuit locked itself onto a path that it has recently been forced to reex-
amine.240 It may have been sensible for the court to reason by analogy to
existing therapeutic biological substances when first addressing the patenta-
bility of DNA, but the court should remain vigilant to the possibility that
new scientific and economic developments might undermine the utility of
234. See Schauer, supra note 121, 537 (asserting that rules are desirable so long as they
are applied as "rules of thumb, useful but intrinsically unweighty indicators of the results
likely to be reached by direct application of reasons"); see also Ronald A. Cass, Judging:
Norms and Incentives of Retrospective Decision-Making, 75 B.U. L. REv. 941, 942 (1995)
(noting that, although he rejected the view of the law as a system of formulas for judges to
mechanically apply, Oliver Wendell Holmes stressed the importance of anchoring the law
within a framework of predictable rules); Kaplow, supra note 232, at 585-86 (noting that the
desirability of giving content to a rule ex ante as opposed to giving content to a standard ex
post depends upon the frequency with which the particular issue arises).
235. See Schauer, supra note 234, at 547 (advocating this regime and explaining that it
would have the advantages of stability of predictability, but also retain the flexibility neces-
sary to ensure that the law does not deviate from its underlying social goals).
236. Bilski v. Kappos, 130 S. Ct. 3218, 3221 (2010).
237. See Posner, supra note 212, at 683-84 ("There are bound to be formalist pockets in
a pragmatic system of adjudication, notably decision by rules rather than by standards").
238. See Utility Examination Guidelines, 66 Fed. Reg. 1092-02, 1095 (Jan. 5, 2001).
239. Parke-Davis & Co. v. H.K. Mulford Co., 189 F. 95 (S.D.N.Y. 1911), aff'd in part,
rev'd in part, 196 F. 496 (2d Cir. 1912).
240. See Ass'n for Molecular Pathology v. U.S. Patent & Trademark Office (AMP), 653
F.3d 1329 (Fed. Cir. 2011) (in a divided opinion, overruling the district court's decision that
claims to isolated and purified DNA sequences constituted unpatentable subject matter), va-
cated, 467 Fed. App'x 890 (Fed. Cir. 2012).
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that analogy. 241 Drawing parallels to the most similar precedents makes
sense when there is insufficient information to justify forging a new legal
path for a novel invention. Yet the Federal Circuit must be mindful of the
possible negative consequences of following this course. It may become
apparent over time that the downsides of rigid adherence to precedent out-
weigh the advantages of stability and predictability. The beneficiaries of the
patent law will be better served if the Federal Circuit candidly exercises ju-
dicial discretion rather than obscuring judicial policymaking in the guise of
formalist reasoning.
Expressly pragmatic patent adjudication would better align patent law
with copyright law. Courts considering the levels of abstraction problem in
copyright cases refrain from absolutist rules and instead employ a more
flexible analysis that takes into account real-world economic factors. 24 2 An
openly pragmatic approach would also harmonize patent law with modern
antitrust jurisprudence. 243 Such harmony is particularly pressing given the
two fields' frequent intersection. The patent and antitrust regimes represent
complementary systems, as both are designed to maximize long-run social
welfare by promoting innovation and competition. 2" The need for harmony
is further pressing in light of the Federal Circuit's 1998 decision to no long-
er apply original circuit antitrust precedent but rather to develop and apply
241. Application of the "human intervention" doctrine to biotechnological inventions
may have been pragmatic in the early days of biotech research, but its utility today is ques-
tionable in light of current scientific understandings. See Eileen Kane, Patent-Mediated
Standards in Genetic Testing, 2008 UTAH L. REv. 835, 890-91 (explaining that, unlike other
types of molecules, the commercial utility of genes and proteins stems mainly from their in-
formational content and does not derive from isolation and purification as it does in the classic
human intervention cases).
242. Chiang, supra note 71, at 1140-41.
243. See, e.g., State Oil Co. v. Khan, 522 U.S. 3, 20-21 (1997) ("[T]he general presump-
tion that legislative changes should be left to Congress has less force with respect to the
Sherman Act in light of the accepted view that Congress 'expected the courts to give shape to
the statute's broad mandate by drawing on common-law tradition.' ").
244. Intergraph Corp. v. Intel Corp., 195 F.3d 1346, 1362 (Fed. Cir. 1999) ("The patent
and antitrust laws are complementary, the patent system serving to encourage innovation and
the bringing of new products to market by adjusting investment-based risk and the antitrust
laws serving to foster industrial competition."); Atari Games Corp. v. Nintendo of Am., Inc.,
897 F.2d 1572, 1576 (Fed. Cir. 1990) ("[Tihe aims and objectives of patent and antitrust laws
may seem, at first glance, wholly at odds. However, the two bodies of law are actually com-
plementary, as both are aimed at encouraging innovation, industry and competition."); U.S.
Dep't of Justice and Fed. Trade Comm'n, Antitrust Guidelines for the Licensing of Intellectu-
al Property § 1.0 (1995), available at http://www.justice.gov/atr/public/guidelines/0558.pdf
("The intellectual property laws and the antitrust laws share the common purpose of promot-
ing innovation and enhancing consumer welfare."); see also Thomas 0. Barnett,
Interoperability Between Antitrust and Intellectual Property, 14 GEo. MASON L. REv. 859,
860 (2007) (explaining that competition reduces static inefficiency by driving prices toward
marginal costs of production, but at the risk of increasing dynamic inefficiency if the drive
towards marginal costs occurs too early in the product development timeline, and that this
insight suggests that "intellectual property protection is not separate from competition princi-
ples, but rather, is an integral part of antitrust policy as a whole").
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its own antitrust jurisprudence in patent cases.2 45 The Federal Circuit could
improve the interoperability of patent and antitrust law by incorporating
pragmatic aspects of antitrust decisionmaking into its patent jurispru-
dence.2 46
Antitrust law employs an amalgam of flexible standards and bright-line
rules that enables courts to transparently engage in policy engineering. Em-
pirical questions are resolved through various procedural mechanisms that
force parties to produce the key information courts need in order to fit the
law to different factual circumstances.2 47 The Sherman Act's sweeping provi-
sions give courts a great deal of discretion to adapt antitrust policy to
changing market conditions and to new learning about the economic effects of
the competitive process t Some actions, such as price-fixing or bid-rigging,
are per se unreasonable restraints of trade because courts have concluded from
past experience that they are manifestly anticompetitive and socially undesir-
able.249 Other restraints are judged under a loose "rule of reason" standard.
Conduct that does not fall into a per se prohibited category must undergo a
highly contextual, fact-intensive analysis in order for judges to ascertain
whether the conduct is, on balance, anticompetitive or procompetitive. Simi-
larly, the Clayton Act employs an amalgam of rules and standards, as it
prohibits certain activities, such as price discrimination, tying, and certain
acquisitions, but only where the effect of the arrangement may be to sub-
245. Nobelpharma AB v. Implant Innovations, Inc., 141 F.3d 1059, 1067 (Fed. Cir.
1998).
246. See Barnett, supra note 244, at 870 ("[F]irms making investment decisions seek
clear, predictable rules as to how the intellectual property and antitrust regimes will function
together-or interoperate.").
247. See A. Douglas Melamed & Ali M. Stoeppelwerth, The CSU Case: Facts, Formal-
ism and the Intersection of Antitrust and Intellectual Property Law, 10 GEO. MASON L. REV.
407 (2002) (criticizing the Federal Circuit's decision in In re Independent Service Organiza-
tion Antitrust Litigation (CSU), 203 F.3d 1322 (Fed. Cir. 2000), which held that patentees
may lawfully refuse to sell or license their patent rights if they do not engage in a per se viola-
tion of the antitrust laws such as illegal tying or fraud and arguing that the decision runs
against the grain of the current trend in antitrust law moving away from adjudicative rule
formalism and towards a contextual analysis that applies economic principles to distinguish
anticompetitive and precompetitive conduct).
248. 15 U.S.C. § 1 (2011) ("Every contract, combination in the form of trust or other-
wise, or conspiracy, in restraint of trade or commerce among the several States, or with
foreign nations, is declared to be illegal."); id. § 2 ("Every person who shall monopolize, or
attempt to monopolize, or combine or conspire with any other person or persons, to monopo-
lize any part of the trade or commerce among the several States, or with foreign nations, shall
be deemed guilty of a felony."); see also JOHN i. SHENEFIELD & IRWIN M. STELZER, THE
ANTITRUST LAWS 15-19 (4th ed. 2001) (explaining that when drafting the Sherman Act, Con-
gress did not delineate lists of prohibited activities, but rather chose to proscribe restraints
generally, in sweeping provisions to be developed and applied by courts in specific cases).
249. SHENEFIELD & STELZER, supra note 248, at 16-17 ("Some practices, while sub-
jected to what courts call per se treatment, nevertheless are evaluated by reference to market
circumstances . .. . Others are condemned outright, without any such further analysis. But
those latter instances are increasingly rare.").
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stantially reduce competition or to create a monopoly.250 As Judge Posner
notes:
It is only because the courts (following dominant economic opinion)
are confident that the ordinary garden-variety cartel or price-fixing
agreement is socially inefficient that there is a rule against cartelizing
or price fixing .... When the judges' confidence in the competitive
significance of a challenged practice is sufficiently shaken . . . they
engage in a more freewheeling inquiry.25'
Although the Patent Act comprises a more detailed statutory scheme
than the antitrust laws,252 the Federal Circuit retains a significant amount of
discretion to carry out its central goal of promoting innovation. The broadly
defined statutory requirements, supplemented by longstanding judicially
created doctrines, leave much room for the court to develop an approach to
patent adjudication patterned after antitrust law.
The PSM doctrine is the best doctrinal vehicle to perform explicit poli-
cy-based patent tailoring. Engaging in a contextual approach to patent
adjudication allows courts to adapt to non-technological changes, such as
new regulations and shifting market conditions, which impact the incentives
of inventors and developers. For example, if the federal government were to
significantly slash its NIH budget or substantially change FDA safety and
efficacy requirements, the level of skill in the biopharmaceutical arts would
not change, but incentives to invent biotechnologies could be significantly
affected. Unlike the disclosure requirements, the PSM doctrine is not (os-
tensibly) tied by the PHOSITA to strictly technological considerations.2 53
Hence, use of the PSM doctrine to calibrate the reach of claims into after-
arising technology would not risk departure of patent doctrine from scientific
250. Id. at 21.
251. RICHARD POSNER, ANTITRUST LAW 39-40 (2d ed. 2001); see also Continental
T.V., Inc. v. GTE Sylvania Inc., 433 U.S. 36 (1977) (rejecting application of the Sherman Act
to nonprice vertical restraints which rested upon a formalist distinction between sales and
consignments and clarifying that adjudication of antitrust cases must center on the challenged
activity's demonstrable economic consequences). But see David F. Shores, Economic Formal-
ism in Antitrust Decisionmaking, 68 ALB. L. REV. 1053 (2005) (cautioning that recent
antitrust case law purporting to emphasize demonstrable economic effects actually relies on
abstract economic theory that has not been empirically tested, and thus manifests economic, as
opposed to legal, formalism).
252. Plager & Pettigrew, supra note 228, at 1737 (asserting that the Federal Circuit's
discretion is more limited than is the discretion of courts hearing antitrust cases, because the
Patent Act comprises a detailed statutory scheme and the Federal Circuit is constrained by
congressional policy choices embedded in the legislation).
253. See Menell, supra note 220, at 489-90 (noting that doctrines tied to the PHOSITA
standard cannot adequately take into account critical variables relevant to optimal patent
scope, including the costs of creation and invention, alternative means of appropriating the
value of inventions, and network effects).
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reality.25 It would also increase transparency by alerting inventors and de-
velopers to the basis for the court's decisions. Litigants would not be left to
wonder whether a patentability determination that seems at odds with cur-
rent scientific knowledge reflects either the Federal Circuit's
misunderstanding of the state of the relevant art or the court's implicit con-
sideration of economic and market considerations. A more expansive,
scope-defining PSM doctrine might obviate the need for a separate written
description requirement for originally filed claims.2 55 It would also allow the
court to assess enablement by reference to the embodiment described in the
specification, preventing contortion of the enablement doctrine through se-
lective application of the full-scope rule or reasonable correlation test.2 56
This Article's proposal comports with Dan Burk and Mark Lemley's
pragmatic argument that a touchstone of patentability should be whether or
not the public is already deriving benefit from a newly discovered substance
or property.257 The proposed approach also centers on the practical implica-
tions of patenting but goes a step further by asserting that patent eligibility
should explicitly turn on the patent's net social benefits. Even if the public is
not already deriving benefit from a newly discovered phenomenon, allowing
the inventor to patent that discovery may nonetheless be welfare-reducing if
it significantly impedes follow-on development.
Importantly, pragmatism favors using the PSM doctrine as a "backstop"
that prevents the patenting of inventions that satisfy other statutory patenta-
bility criteria but nonetheless should, in the interests of innovation policy,
remain in the public domain. 258 The Federal Circuit should first assess
whether the claim meets the requirements of novelty, nonobviousness, utili-
ty, and adequate disclosure (according to the single-embodiment rule).
254. Claim construction is of limited utility in tailoring patent scope to achieve utilitari-
an aims so long as the plain meaning of the claim's language is acknowledged. Morse's eighth
claim illustrates why we must go beyond claim language if we are to set meaningful limits on
the reach into after-arising technologies. See Lemley et al., supra note 78, at 1332-33.
255. See Jeffrey A. Lefstin, The Formal Structure of Patent Law and the Limits of Ena-
blement, 23 BERKELEY TECH. L.J. 1141 (2008) (explaining that the written description
requirement allocates proprietary rights among pioneering inventors and follow-on developers
by restricting claim scope to a particular level of abstraction). The written description re-
quirement would still be useful to assess the priority date of claims that are added after the
filing date of the original application. The question would be whether the specification ade-
quately describes the subject matter of the after-filed claims such that the patentee possessed
the later-claimed invention on the filing date.
256. See Chiang, supra note 71, at 1147-49 (explaining that, so long as we think that
patentees ought to be able to claim some subset of after-arising technologies, enablement is an
awkward tool to make determinations of how large that subset should be).
257. Dan L. Burk & Mark A. Lemley, Inherency, 47 WM. & MARY L. REv. 371, 407-08
(2005) (arguing that if a newly discovered phenomenon already provides public benefit then it
should be unpatentable under the inherency doctrine); see also Schering Corp. v. Geneva
Pharm., 339 F.3d 1373 (Fed. Cir. 2003) (adopting Burk and Lemley's reasoning).
258. See Lemley et al., supra note 78 (advocating this approach); see also Chiang, supra
note 83, at 1397 ("Ideally, scope delineation should be the last exercise performed by a court
or the USPTO, because it is the most complicated and administratively expensive inquiry.").
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Then, only if a claim meets each of these criteria should the court proceed
with a forward-looking PSM analysis that grapples with the levels of ab-
straction problem. This approach would enable the court to employ the "take
the best" heuristic, which instructs the decisionmaker to act on a single valid
cue and ignore other less reliable forms of evidence. 259 Interestingly, the
Federal Circuit took this approach in Ariad when it deviated from estab-
lished custom of treating PSM as a threshold inquiry, sidestepping the PSM
question and electing instead to invalidate the claim on written description
grounds. 260
The tailoring functions performed by the PSM doctrine may be supple-
mented by judicious application of the standard for injunctive relief.
Limiting the remedy for infringement to a monetary award mitigates the
potential harmful effects of questionable validity determinations. 26 1 Where
available empirical data suggest that a particular type of upstream patent
could deter innovation, pragmatism favors upholding the validity of the pa-
tent but denying injunctive relief. Under this approach, the court would
signal its willingness to revisit the validity issue at a later time as additional
information about the technology develops and more becomes known about
the impact of such patents on technological progress.
Expressly pragmatic adjudication would arguably create greater legal
predictability than the Federal Circuit's current practice of feigned formal-
ism.262 Even if a shift to pragmatism does increase short-term legal
instability, it could ultimately increase long-term stability by facilitating
private ordering. This Article's proposed approach highlights the fact that
patents are inherently uncertain probabilistic rights governed by muddy
rules. 263 Game theory predicts that muddy rules will promote efficient
259. See VERMEULE, supra note 107, at 180 (generally explaining the "take the best"
heuristic).
260. Ariad Pharm. v. Eli Lilly & Co., 598 F.3d 1336, 1358 (Fed. Cir. 2010) (en banc)
(concluding that since the invention was unpatentable for lack of an adequate written descrip-
tion the court need not address other validity issues).
261. See Smith, supra note 24, at 2127 (explaining that an injunction denial can operate
as a "safety valve" to reach desirable outcomes in situations in which the holdup threat is
particularly concerning, forestalling the need for more aggressive legislative or judicial re-
forms); see also Michael W. Carroll, Patent Injunctions and the Problem of Uniformity Cost,
13 MICH. TELECOMM. & TECH. L. REV. 421 (2007) (explaining that flexibility in the standard
for injunctive relief should lead to industry-specific patterns in its application because of in-
dustry-specific facts relevant to the standard).
262. See Carroll, supra note 23, at 1428-29 (explaining that increased complexity asso-
ciated with patent tailoring will not necessarily produce greater administrative costs, and that
greater complexity may actually reduce licensing and litigation costs if it produces legal ter-
minology with comparatively stable meaning).
263. See Mark Lemley & Carl Shapiro, Probabilistic Patents, 19 J. EcoN. PERSPECTIVES
75 (2005) (delineating the numerous uncertainties associated with patent rights); Carl Shapiro,
Antitrust Limits to Patent Settlements, 34 RAND J. EcoN. 391, 395 (2003) (noting that "all real
patents are less strong than the idealized patent grant usually imagined in economic theory"
because what a patent provides is not a right to exclude "but rather the more limited 'right to
try to exclude' by asserting its patent in court"); Kelly Casey Mullally, Legal (Un)certainty,
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transactions because parties are more willing to negotiate and less inclined
to engage in strategic behavior where each party has a probabilistic claim.26
This suggests that some legal uncertainty about the scope of patent claims is
not only acceptable, but may actually increase social welfare.
B. Institutional Considerations
Envisioning an explicit lever for patent scope raises questions of politi-
cal economy and relative institutional competence. If we are to develop
evidence-based patent law, why should the Federal Circuit, rather than the
USPTO or Congress, be the entity to take the lead in patent policy engineer-
ing?265 Patent reform proposals must be mindful of the "nirvana fallacy," the
phenomenon whereby "an excessively optimistic account of one institution
is compared with an excessively pessimistic account of another."2 66 The in-
stitutional decision necessarily involves a choice among highly imperfect
altematives.2 67 Key factors to consider include relative expertise, respon-
siveness to public opinion, procedural differences, political insulation, and
susceptibility to capture. 2 68
The USPTO is not the best institution to formulate evidence-based pa-
tent law, because it lacks substantive rulemaking authority and economic
Legal Process, and Patent Law, 43 Lov. L.A. L. REV. 1135, 1135-41 (2010) (explaining that,
contrary to the general presupposition that private actors favor legal clarity, patent applicants
have incentives to introduce uncertainty into their patents by drafting broad claims intended to
cover unknown future technologies and to capture all possible infringements).
264. Ian Ayres & Eric Talley, Solomonic Bargaining: Dividing a Legal Entitlement to
Facilitate Coasean Trade, 104 YALE L.J. 1027 (1995) (characterizing muddy rules as an ex-
ample of divided entitlements and showing that divided entitlements promote efficient
transactions).
265. See Carroll, supra note 23, at 1400 (noting that intellectual property can be tailored
by judicial adjudication, administrative rules and adjudication, or by legislation); VERMEULE,
supra note 7, at 64 ("[Slpecifying a criterion for a successful interpretive outcome ... says
nothing at all about which institution is best situated to implement the chosen aim . . .
266. VERMEULE, supra note 7, at 40; see also Harold Demsetz, Information and Effi-
ciency: Another Viewpoint, 12 J.L. & ECON. 1 (1969) (identifying the nirvana fallacy and
arguing in favor of a comparative institutional approach).
267. See Rai, supra note 109, 1039 (2003) ("Only by evaluating the relative competence
of the various institutions in performing the tasks required by the patent process can we hope
to design a system that works reasonably well-or, at a minimum, less imperfectly than the
alternatives."). See generally NEIL K. KOMESAR, IMPERFECT ALTERNATIVES: CHOOSING IN-
STITUTIONS IN LAW, ECONOMICS, AND PUBLIC POLICY 4-6 (1994) (asserting that comparative
institutional analysis is essential to addressing public policy questions and that "tasks that
strain the abilities of an institution may wisely be assigned to it anyway if the alternatives are
even worse").
268. Masur, supra note 17, at 31-32. Public choice theory assumes that government
actors are influenced by their own personal motives when making decisions that impact social
welfare, and thus are subject to capture by powerful special interests. See, e.g., Roger G. Noll,
Economic Perspectives on the Politics of Regulation, in 2 HANDBOOK OF INDUSTRIAL ORGAN-
IZATION 1253, 1262-63 (Richard Schmalensee & Robert D. Willig eds., 1989) (arguing that
public actors will effectuate policies that do not reflect the interests of citizens if adequate
monitoring and enforcement mechanisms are not instituted).
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expertise. 269 Absent rulemaking authority, it is not capable of fine-tuning
patent law to keep it abreast with evolving social needs. Even if Congress
were to grant the USPTO rulemaking authority, the agency's capacity to
competently exercise such authority is questionable. 270 Patent examiners are
not lawyers-they merely perform the ministerial function of administering
the law created by Congress and the courts.271 The USPTO's policymaking
capability would be strengthened if it were granted the authority and re-
sources to tackle the complex economics of patent scope.272 But even an
agency with increased authority and resources would still remain hampered
by the inherent limitations of ex ante rules applied to heterogeneous and
constantly evolving technologies. Also, it may be unduly costly to center the
focus of patent tailoring on the USPTO. Very few patents have real market-
place value-the majority are neither licensed nor litigated273-So it would
be wasteful for the USPTO to expend substantial resources performing de-
tailed examinations. 274
The Federal Circuit is a better venue than the USPTO to elicit the in-
formation required to answer empirical questions about the practical effects
of patents. The court has the advantage of being able to take into account
scientific and market developments that occur after a patent issues.275
only become apparent with the benefit of time that an upstream inventor was
granted a disproportionately broad patent that threatens to stifle follow-on
269. Benjamin & Rai, supra note 113, at 47 (explaining that the USPTO does not en-
gage in substantive rulemaking and currently lacks the expertise to formulate innovation
policy).
270. See, e.g., Rai, supra note 109, at 1132-33; John R. Thomas, The Responsibility of
the Rulemaker: Comparative Approaches to Patent Administration Reform, 17 BERKELEY
TECH. L. J. 727, 742-43 (2002). But see Masur, supra note 17, at 304-07(arguing that the
USPTO would do a better job than the Federal Circuit at setting patent policy if given substan-
tive rulemaking authority).
271. Orin S. Kerr, Rethinking Patent Law in the Administrative State, 42 WM. & MARY
L. REV. 127, 138-40 (2000) ("The [USPTO] and its over three thousand patent examiners
serve a narrowly circumscribed role in the private law patent system. The [USPTO] has a
ministerial task: to apply a legal standard determined by Congress and the courts to the facts
presented to it by the patent applicant.").
272. See Masur, supra note 17 (arguing that the USPTO should be granted substantive
rulemaking authority).
273. Gideon Parchomovsky & R. Polk Wagner, Patent Portfolios, 154 U. PA. L. REV. 1,
18-19 (2005).
274. See Mark A. Lemley, Rational Ignorance at the Patent Office, 95 Nw. U. L. REV.
1495, 1497 (2001) ("In short, the [USPTO] doesn't do a very detailed job of examining pa-
tents, but we probably don't want it to. It is 'rationally ignorant' of the objective validity of
patents, in economics lingo, because it is too costly for the [USPTO] to discover those
facts.").
275. Dan L. Burk & Mark A. Lemley, Fence Posts or Sign Posts?: Rethinking Claim
Construction, 157 U. PA. L. REV. 1743, 1782 (2009) ("[I]nnovations that are worth fighting
for sort themselves out over time and [can be] vetted by the institution best able to make an ex
post determination regarding patent value and scope: the courts."); see also DAN L. BURK &
MARK A. LEMLEY, THE PATENT CRISIS AND HOW THE COURTS CAN SOLVE IT 95 (2009)
(arguing that the courts are the best institutions for patentability analysis).
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development. 27 6 In addition, the court can assess the scope of an upstream
invention by reference to a concrete situation involving a specific after-
arising technology. The United States' adversarial judicial system is founded
on the premise that those who have the most at stake in the outcome will
produce the best research and make the best arguments. As Mark Lemley
notes: "On this view . . . accused infringers . . . will do a better job of prov-
ing a patent invalid than an examiner ever could." 27 7 The Federal Circuit
may also be less susceptible to capture than the USPTO. Agency officials
may be influenced by the narrow interests of the patent applicants who sup-
ply the bulk of the information used to make patentability determinations. 278
Tenured judges tend to have more secure salaries and budgets than agency
officials, and may have a greater desire for prestige than other enticements
that powerful interest groups can readily provide. 279
The Federal Circuit is also better equipped than Congress to engage in
comprehensive patent tailoring. Legislative discretion is constrained by the
Agreement on Trade-Related Aspects of Intellectual Property ("TRIPs"),
which prohibits member states from discriminating based on technology in
their grant of patent rights. 28 0 Even if legislative tailoring is legally permis-
sible, it may not be desirable. A statute is too blunt an instrument to capture
the context-dependent predictions of patent theory.28' Because the legislative
process is slow, legislatures tend to make substantial changes to the law
when they garner the momentum to act. In contrast, judicial lawmaking
tends to be more precise because it develops incrementally on a case-by-
case basis. 282 Congress may be too sluggish and inflexible to keep pace with
276. See Merges & Nelson, supra note 32, at 845-48 (noting that it is difficult to resolve
issues like the "undue experimentation" facet of the enablement requirement when a patent is
filed, because at that point no one knows how the technology will evolve or how much work
will be required to develop follow-on innovations); Chiang, supra note 71, at 1137 ("If-as is
almost certainly the case-judges have a difficult time determining optimal scope after-the-
fact because of the complexity of the inquiry; then it is almost impossible to imagine how
Congress or the [USPTO] will have the capability to determine a method of computing opti-
mal scope before-the-fact, when less information is available.").
277. Lemley, supra note 274, at 1522.
278. See Benjamin & Rai, supra note 113, at 36-37 (noting that agency officials are
most susceptible to capture by those interests who disproportionately supply the information
upon which agency decisions are made).
279. Id. at 38 (noting that the prevailing view among commentators is that courts are less
likely than agencies to be captured). But see Masur, supra note 17, at 28 (arguing that there is
no reason to believe that the USPTO is particularly susceptible to capture, and suggesting that
the Federal Circuit may have been captured by private interests).
280. Burk & Lemley, supra note 3, at 1634.
281. Id. at 1635 ("Many of the predictions of economic theory are fact-specific--they
suggest different factors that should bear on the outcome of particular cases, but that require
case-by-case-adjudication that cannot be easily captured in a statute.").
282. Shyamkrishna Balganesh, The Pragmatic Incrementalism of Common Law Intellec-
tual Property, 63 VAND. L. REV. 1543, 1592-93 (2010).
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fast-moving technological change. 283 It also may be more susceptible than
the Federal Circuit to capture by rent-seeking special interests.284
Congress has displayed neither the inclination nor the capacity to tackle
difficult questions of patent scope. The language and legislative history of
the Patent Act strongly suggest that Congress intended to delegate signifi-
cant policymaking authority to the courts. 285 Legislators passed the Patent
Act of 1952 with shockingly little idea of the statute's content and mean-
ing." 6 The legislative decision to rely primarily on statutory standards rather
than rules reflects an expectation that courts would exercise judicial discre-
tion when determining patentability.2 87 By historical standards, a new
version of the Patent Act was due when Congress created the Federal Circuit
in 1982, and thus Congress's decision to establish the court rather than enact
new patent legislation could be seen as a delegation of patent policymaking
authority to the Federal Circuit.s Although Congress has intervened in
283. See Dreyfuss, supra note 13, at 779 (arguing that Congress is ill-suited to the task
of tailoring patent law, because "[t]he complexity, frequency, and pace of [scientific and mar-
ket] changes far outstrip Congress's capacity to legislate"); Robert P. Merges, One Hundred
Years of Solicitude: Intellectual Property Law, 1900-2000, 88 CALIF. L. REV. 2187, 2190
(2000) (arguing that the intellectual property system works best when the courts have "legisla-
tive slack" to adapt the law to new technologies); Burk & Lemley, supra note 3, at 1636-37
(offering as an example the Semiconductor Chip Protection Act designed to protect semicon-
ductor mask works, which has virtually never been used because changes in the way chips are
made quickly rendered it obsolete).
284. See KOMESAR, supra note 267, at 124 (explaining that federal judges' job security,
their general disinterest in alternative employment opportunities, and steep penalties associat-
ed with financial inducement of judges make judges less susceptible than elected officials to
influence peddling); Benjamin & Rai, supra note 113, at 40-42 (arguing that recent attempts
at legislative patent reform reflect the problem of congressional capture, because long-term
considerations of social welfare tend to be overshadowed by competing short-term interests of
patent-dependent life sciences firms and comparatively patent-independent information tech-
nology firms); POSNER, supra note 193, at 253 (noting that, in contrast to legislators who rely
on campaign contributions from powerful interest groups, judges' compensation is not tied to
their decisions in particular cases).
285. See Menell, supra note 83, at 1309 (arguing that when Congress enacted the Patent
Act of 1952, it intended for courts to continue the jurisprudential tradition of "drawing upon
statutory, constitutional, common sense, and experiential sources and insights [so as to ensure
that the patent system evolved] into a workable, dynamic system").
286. See WILLIAM KINGSTON, BEYOND INTELLECTUAL PROPERTY: MATCHING INFOR-
MATION PROTECTION TO INNOVATION 87 (2010) (noting that Federal Circuit Judge Rich, who
was a patent attorney at the time and a main drafter of the act, later explained, "The [1952]
Patent Act was written basically by patent lawyers ... A good 95% of the members [of Con-
gress] never knew that the legislation was under consideration, or that it had passed, let alone
what it contained").
287. Michael W. Carroll, A Review of Recent Decisions of the United States Court of
Appeals for the Federal Circuit: One for All: The Problem of Uniformity Cost in Intellectual
Property, 55 AM. U. L. REV. 845, 895 (2006); see also Masur, supra note 17, at 13 ("It makes
no sense to pretend that Congress somehow managed to embed the proper [patent] rules into
the [Patent] Act's terse language in 1952 (and before), and that the courts need merely divine
Congress's intent.").
288. Dreyfuss, supra note 9, at 837 (suggesting that Congress's creation of the Federal
Circuit in 1982 reflects its implicit delegation of patent policymaking authority to the court).
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patent matters since the Federal Circuit's inception, 289 these statutory chang-
es neither substantially altered the standards for patentability nor directly
addressed the permissible scope of patent claims.
Admittedly, the Federal Circuit faces practical limitations in its ability
to evaluate complex economic data. Yet Congress may be even less suited to
this task.290 The nature of the litigation process provides courts with a com-
parative advantage over legislatures to contextualize the patent law. Judges,
unlike legislators, create the law by reference to concrete sets of facts and
need not imagine all of the possible ramifications of their decisions ex
ante.291 The Federal Circuit routinely confronts highly technical expert tes-
timony in drawing conclusions about patent validity and infringement, so it
should be capable of evaluating empirical data regarding the balance of in-
centives in industries characterized by cumulative innovation should not
pose a unique challenge. Congress may generally be better able than courts
to ascertain public norms and interest group preferences.2 92 However, as a
specialist court, the Federal Circuit has greater capability than generalist
courts to appreciate "legislative intentions, interest-group deals, statutory
policies, and social and economic consequences" of its decisions. 29 3 The
Federal Circuit will not be unduly burdened if it adopts an incremental ap-
proach in which it asks relevant empirical questions, creates incentives for
the affected parties to seek answers, and proceeds cautiously as the fund of
information accumulates over time.
The Delaware Chancery Court's corporate law jurisprudence offers an
exemplary adjudicative model for the Federal Circuit. Like patent law,
corporate law grapples with the challenge of formulating a regulatory
scheme that applies to a wide range of private actors amidst constantly
289. Congress has intervened in patent matters since the Federal Circuit's inception in
several instances: it has altered the patent term for pharmaceutical patents, carved out experi-
mental use defenses for generic pharmaceutical manufacturers, prohibited enforcing patents
on medical procedures against doctors, and created a prior user defense against business
method patents. Most recently, Congress passed the Leahy-Smith America Invents Act which,
inter alia, changes the patent system from a first-to-invent to a first-to-file priority regime and
expands post-grant opposition proceedings at the USPTO.
290. See James J. White, Phoebe's Inment, 98 MICH. L. REV. 2773 (2000) (discussing
the lack of influence empirical work has on legislators). Although the Federal Circuit tends to
ignore the uncomfortable problem of imperfect information, other courts have freely acknowl-
edged a similar problem in the copyright context. See, e.g., Nash v. CBS, Inc., 899 F.2d 1537,
1541 (7th Cir. 1990) ("Neither Congress nor the courts has the information that would allow it
to determine [optimal copyright scope]. Both institutions must muddle through.").
291. Kaplow, supra note 232, at 609 (making this observation).
292. See VERMEULE, supra note 7, at 65 (explaining that Congress's greater susceptibil-
ity to capture must be weighed against judges' comparative informational deficits stemming
from their insularity).
293. Id. at 74-75 (explaining why a specialist court is generally better able than a gener-
alist court to adopt an anti-formalist adjudicative approach): see also Sunstein & Vermeule,
supra note 109, at 888, 922-23 (noting that anti-formalism may be better suited to specialist
judges than to generalist judges).
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evolving economic and market conditions. 294 By wide margins, Delaware
is the favored state for incorporation.295 Several commentators have
attributed Delaware's corporate law preeminence to the excellence of its
judiciary. 29 6 Recognized benefits of Delaware courts' adjudicative approach
include "flexibility, responsiveness, insulation from undue influence, and
transparency." 297 The shared expertise of the specialized court and bar
generates a body of corporate law that is attuned to empirical uncertainty 298
and quickly incorporates new information. Instead of employing an
exclusively rules-based or standards-based approach, Delaware courts blend
the two strategies together to balance predictability and adaptability. 299
Although fiduciary duty law rests upon vague concepts such as the "duty of
care" and the "duty of loyalty," several cognizable rules have emerged
294. See Jill E. Fisch, The Peculiar Role of the Delaware Courts in the Competition for
Corporate Charters, 68 U. CIN. L. REV. 1061, 1099 (2000) (identifying these challenges with
respect to corporate law). The Federal Circuit's task may be easier than that of the Delaware
chancery courts, because, in contrast to the corporate law, there is widespread consensus on
the patent law's ends. Compare William Klein, Criteria for Good Laws of Business Associa-
tion, 2 BERKELEY Bus. L.J. 13 (2005) (identifying fairness, economic goals, political control
and reducing administrative costs as possible goals of the corporate law), with Andrew S.
Gold, A Decision Theory Approach to the Business Judgment Rule: Reflections on Disney,
Good Faith, and Judicial Uncertainty, 66 MD. L. REV. 398, 437-40 (2007) (noting that there
is a wide range of theoretical disagreement over the ends of corporate law).
295. William J. Carney & George B. Shepherd, The Mystery of Delaware Lnws Contin-
uing Success, 2009 U. ILL. L. REV. 1, 3 ("During the period 1996-2000, 58% of all publicly
held firms and 59% of the Fortune 500 Industrial firms were incorporated in Delaware. Dur-
ing the period 1978-2000, 56% of all initial public offerings ('IPOs') involved Delaware
corporations.").
296. See, e.g., Bernard S. Black, Is Corporate Law Trivial?: A Political and Economic
Analysis, 84 Nw. U. L. REV. 542, 589-90 (1990) (concluding that judicial expertise is the
main reason for Delaware's dominance in the state competition for corporate charters); see
also ROBERTA ROMANO, THE GENIUS OF AMERICAN CORPORATE LAw 39-40 (1993); Marcel
Kahan & Ehud Kamar, The Myth of State Competition in Corporate Law, 55 STAN. L. REV.
679, 708 (2002). But see Carney & Shepherd, supra note 295 (arguing that Delaware corpo-
rate law has become increasingly indeterminate because the Delaware Chancery Court has
transformed the standards of care, good faith, and loyalty into a convoluted series of mini-
rules).
297. Fisch, supra note 294, at 1064.
298. Gold, supra note 294 (arguing that the empirical uncertainty that surrounds debates
over the duty of good faith suggests that a rational basis test is appropriate to assess claims of
subjective failings or improper motivations).
299. Cunningham, supra note 233, at 1436 ("Corporate law is a mixture of rules and
principles whose application and interaction generates a rich, complex tapestry that diminishes
the utility of any such tidy classifications."); William T. Quillen & Michael Hanrahan, A Short
History of the Delaware Court of Chancery-1 792-1992, 18 DEL. J. CORP. L. 819, 820 (1993)
("Delaware's Court of Chancery has never become so bound by procedural technicalities and
restrictive legal doctrines that it has failed the fundamental purpose of an equity court-to
provide relief suited to the circumstances when no adequate remedy is available at law.");
Fisch, supra note 294 (explaining that Delaware chancery courts employ a distinctive process
for developing corporate law that in some respects resembles legislation and in other respects
resembles the work of an administrative agency).
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through the adjudication process."' Delaware corporate law is reasonably
determinate because it has been developed through a series of richly detailed
opinions, or "corporate law sermons." 301 Delaware judges actively engage
with the academic corporate law literature 302 and liberally impart
"extrajudicial utterances [that] can be read as attempts to be heard on a
critical matter in the absence of a case raising just the right issue and in the
absence of the articulation (or articulability) of a governing rule."303
Like the Delaware Chancery Court, the Federal Circuit should transpar-
ently engage in policy engineering but tie its decisions to clearly articulated
instrumental objectives. It should acknowledge empirical uncertainty and
create incentives for litigants to fill in those information gaps. When empiri-
cal questions cannot be adequately answered for want of decisive
information, the court should pragmatically refrain from upsetting settled
expectations and adhere to the presumption of patent validity while signal-
ing a willingness to revisit contested issues in response to future
developments. This would ensure that the patent law achieves a desirable
balance between predictability and flexibility.
The Federal Circuit should function as the locus of empirically driven
patent tailoring while promoting a multi-institutional approach to innovation
policy.30 The Supreme Court lacks the time and expertise to tackle the intri-
cacies of patent law, but the Court is well suited to demarcate the
relationships between patent law and other substantive areas.3 05 Contextual
information elicited through the litigation process should also prompt legis-
lative or administrative measures (e.g., statutory changes or modifications of
USPTO regulations) that work in concert with pragmatic patent adjudication
300. Cunningham, supra note 233, at 1442-44 (citing as examples the business judg-
ment rule and rules that have emerged from cases involving alleged breaches of the duty of
loyalty that do not involve self-interested transactions); see also Timothy P. Glynn, Dela-
ware's Vantagepoint: The Empire Strikes Back in the Post-Post-Enron Era, 102 Nw. U. L.
REV. 91, 97-101 (2008) ("Hence, the Delaware courts are the primary source of both the sub-
stance and enforcement of Delaware corporate law. By developing standards through a
careful, contextual approach, rather than via broad pronouncements of unbending general
rules, the courts assure further litigation over corporate legal norms and their application.").
301. Edward B. Rock, Saints and Sinners: How Does Delaware Corporate Law Work?,
44 UCLA L. REv. 1009, 1016 (1997).
302. Carney & Shepherd, supra note 295, at 43-44.
303. Rock, supra note 301, at 1095.
304. Arti K. Rai, Building a Better Innovation System: Combining Facially Neutral
Patent Standards with Therapeutics Regulation, 45 Hous. L. REv. 1037, 1040 (2008) (argu-
ing that we need to avoid "tunnel vision" in thinking about regulatory systems that promote
innovation and recognize that a multi-system approach may be optimal for resolving questions
of innovation policy).
305. Dreyfuss, supra note 9, at 839 (arguing that the Federal Circuit is better able than
the Supreme Court to hone the contours of patent scope and strength, but that the Supreme
Court is well suited to address overarching issues such as the relationship between patent and
antitrust); see also Ill. Tool Works Inc. v. Indep. Ink, Inc., 547 U.S. 28, 34, 43-44 (2006)
(eliminating a per se presumption of market power in tying arrangements involving patented
products and replacing it with a flexible rule-of-reason analysis).
[Vol. 19:43
An Explicit Policy Lever for Patent Scope
to better align the patent law with the patent system's utilitarian purpose.
Additionally, technological advances may raise ethical, social, and moral
issues that may not be conducive to judicial resolution. 306 The Federal Cir-
cuit should focus on calibrating incentives to promote technological
innovation, leaving it to the legislative and executive branches to further
broader social goals. Part C illustrates how the proposed approach could be
applied to recent and ongoing disputes involving the patentability of diag-
nostic and therapeutic methods.
C. Application to Medical Methods
Patent law shapes biomedical innovation in concert with, inter alia, fed-
eral research funding policies, food and drug law, and regulation of the
health insurance industry. 307 The Federal Circuit should acknowledge these
complexities when determining the proper scope of patent protection for
diagnostic and therapeutic methods. Factors to consider when making claim
scope determinations should include financing needs, sources of funding,
and regulatory barriers to entry at each stage of the relevant product devel-
opment life cycle. A related consideration should be the extent to which
patent protection on an upstream discovery is perceived by investors to be
required for downstream development. For example, surveys of venture cap-
ital firms may be utilized to ascertain the effect of upstream patents on the
decision to invest (and at what price) in early-stage life-sciences companies.
Such evidence could be used to discern material differences across diagnos-
tic and therapeutic sectors.
Surveys demonstrate that biopharmaceutical companies and investors
rely heavily on patent exclusivity.308 However, there is an important distinc-
tion between patents covering therapeutic end products and patents covering
the upstream scientific discoveries that lead to new products. It is indisputa-
ble that the former are necessary to incentivize development, but it is less
clear that the latter promote innovation. Patents on pre-market inventions
that explain disease pathways and identify drug targets may actually deter
306. See Dana Remus Irwin, Paradise Lost in the Patent Law? Changing Visions of
Technology in the Subject Matter Inquiry, 60 FLA. L. REV. 775, 819-21 (2008).
307. See Rai, supra note 304, at 1039 (noting that the FDA and the health insurance
industry operate outside the patent system and heavily influence the pharmaceuticals market);
Benjamin & Rai, supra note 113, at 19-21 (explaining how the FDA and NIH work in parallel
with the USPTO and the Federal Circuit to set innovation policy with respect to drugs and
biologics); Arti K. Rai & Rebecca S. Eisenberg, Bayh-Dole Reform and the Progress of Bio-
medicine, 66 L. & CONTEMP. PROBs. 289, 290-91 (2003) (arguing that the level of patent
protection available for biomedical research should take into account the incentive effects of
direct and indirect government financing); John M. Golden, Biotechnology, Technology Poli-
cy, and Patentability: Natural Products and Invention in the American System, 50 EMORY L.
J. 101, 109 (2001) (arguing that patent commentary often overlooks the role of multi-billion
dollar public financing of biomedical research).
308. See, e.g. JAMES BESSEN & MICHAEL J. MEURER, PATENT FAILURE: How JUDGES,
BUREAUCRATS, AND LAWYERS PUT INNOVATION AT RISK 89 (2008).
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progress by driving up the costs of drug development. Upstream discoveries
are often made in university laboratories and then licensed to biopharmaceu-
tical firms who develop and commercialize end products. 3" As Rebecca
Eisenberg observes: "These discoveries are like so many siphons at the feed-
ing trough of new drugs, draining away profits in many different
directions." 310 Empirical data comparing the development and commerciali-
zation of pharmaceutical products targeting proprietary targets with that of
products targeting public domain targets would be highly useful in deter-
mining the proper scope of patent protection for therapeutic methods.
It is also important to distinguish between therapeutics and diagnostics.
The cost of developing a diagnostic test based on a correlation between a
biomarker and a clinical condition is much lower than the cost of bringing a
new therapeutic to market. Whereas the developers of therapeutics must
undergo an arduous FDA approval process, including expensive clinical tri-
als to assess safety and efficacy, the developers of diagnostic tests typically
face minimal regulatory hurdles. 31' Many diagnostic tests are developed in-
house by clinical laboratories ("home brews") and do not undergo extensive
regulatory review. 312 Empirical data comparing the development and com-
mercialization of diagnostic products incorporating proprietary biomarkers
with those incorporating public domain biomarkers would be useful in the
analysis of the proper scope of patent protection for methods of drawing
clinical correlations. Pronouncements by the Federal Circuit that such con-
textual information directly affects patentability will create incentives for
litigants to generate these data.3 13
309. Eisenberg, supra note 56, at 480-81.
310. Id. at 481.
311. See SECRETARY'S ADVISORY COMM. ON GENETICS, HEALTH, AND SOCIETY, U.S.
DEP'T OF HEALTH & Hum. SERVS., GENE PATENTS AND LICENSING PRACTICES AND THEIR
IMPACT ON PATIENT ACCESS TO GENETIC TESTS 34 (2010), available at http://
oba.od.nih.gov/oba/sacghs/reports/SACGHS-patents-report_2010.pdf [hereinafter SACGHS
REPORT] (noting that the costs to develop a diagnostic test are under $10,000). While patents
may not be necessary to incentivize development of simple diagnostic tests, they may be
needed to promote development of more complicated diagnostic products involving complex
associations among numerous biological and environmental phenomena. In his opinion in
Bilski, Justice Kennedy suggested that the patent law draw a distinction between simple corre-
lations and more complex diagnostics. Bilski v. Kappos, 130 S. Ct. 3218, 3227 (2010)
(Kennedy, J., concurring).
312. See Herder, supra note 92, at 200-01 (explaining that diagnostic tests sold as "test
kits" are subject to FDA review and safety, but that all commercially available genetic tests
are marked as "home brews" and thus are not subject to regulatory scrutiny); see also Kane,
supra note 241, at 874 (explaining that if genetic diagnostic tests become subject to FDA
review, researchers engaged in genetic testing may be able to evade infringement liability by
invoking the protection of 35 U.S.C. § 271(e), which creates a safe harbor for activities that
are "reasonably related" to FDA approval; noting this fact as an example of the complicated
nexus between patent law and food and drug law).
313. Although information gaps persist, some empirical data and analyses are available.
See, e.g., SACGHS REPORT, supra note 311 (drawing the following conclusions about the
effects of patents on genetic testing: (1) patents do not accelerate inventive activity; (2) the
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The outcome in Ariad l4 would not change were the Federal Circuit to
re-decide the case under the proposed framework. Since the patentee did not
specifically describe a compound capable of inhibiting NF-idB activity, the
court would invalidate the claims for lack of adequate disclosure without
need to resort to the PSM doctrine. However, under the proposed approach
the court would explicitly acknowledge the levels of abstraction problem
and signal its willingness to consider contextual factors when deciding fu-
ture cases involving slightly different fact patterns. The court's opinion
might explain that the PSM doctrine would come into play were a patentee
in Ariad's position to disclose one or more specific compounds capable of
performing the claimed function. It would further acknowledge that the
MOT test, while a useful rule of thumb when determining PSM in other
contexts, offers little practical guidance with respect to medical method
claims. Finally, the opinion would note that there is no indication that the
discovery of the NF-icB pathway in any way spurred the development of the
allegedly infringing drugs, 315 and would flag for future litigants empirical
uncertainty as to whether patents on disease pathways promote or impede
biopharmaceutical innovation.
In its review of Prometheus 11,16 the Supreme Court correctly reversed
the Federal Circuit's formalist decision that the claims are therapeutic and
thus per se constitute PSM. 3 17 However, the Supreme Court should have
gone further by highlighting the profound disconnect between Federal
Circuit doctrine and the goals of innovation policy. The Supreme Court should
instruct the Federal Circuit to directly confront the limitations of its MOT test
when the Court considers the patentability of gene sequences in its review of
AMP.3 11 Patentability should turn on whether broad proprietary rights are
necessary to encourage both the discovery of gene-disease correlations and
availability of patents is not necessary to promote disclosure of genetic discoveries; (3) patents
have some positive effects on investment in commercial test kits which must be approved by
the FDA; but (4) the development of in-house laboratory tests which do not require FDA ap-
proval does not hinge on patent rights); Heidi Williams, Intellectual Property Rights and
Innovation: Evidence from the Human Genome (Nat'l Bureau of Econ. Research, Working
Paper No. 16213, 2010) (comparing product development stemming from gene sequences that
were temporarily subject to proprietary rights held by the private firm Celera with gene se-
quences that were discovered by the Human Genome Project and immediately transferred into
the public domain; offering an empirical analysis which suggests that Celera's proprietary
rights led to reductions in product development outcomes on the order of 30 percent).
314. Ariad Pharm., Inc. v. Eli Lilly & Co., 598 F.3d 1336 (Fed. Cir. 2010) (en banc).
315. Ariad Pharm., Inc. v. Eli Lilly & Co., 529 F. Supp. 2d 106, 114 (D. Mass. 2007).
The facts of this case are notably similar to those in University of Rochester v. G.D. Searle &
Co., 358 F.3d 916 (Fed. Cir. 2004), where the alleged infringers brought drugs to market even
though they did not have patents on the target itself or methods of inhibiting the targeted en-
zyme.
316. Mayo Collaborative Servs. v. Prometheus Labs., Inc., 132 S. Ct. 1289 (2012).
317. Id. at 1297-98.
318. Ass'n for Molecular Pathology v. Myriad Genetics, Inc., No. 12-398 (U.S. Nov. 30,
2012).
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the development of commercial diagnostic tests. If insufficient data exist to
overcome the presumption of patent validity, the court should uphold the
patent but encourage litigants to revisit the issue in future cases.
Expressly pragmatic patent adjudication should work in tandem with
other institutional efforts to calibrate the scope and strength of proprietary
rights in biological discoveries. Non-judicial interventions to address public
health needs may include legislative initiatives (such as research exemptions
to liability for infringing certain patents) or targeted administrative actions
(such as compulsory licensing or the use of march-in rights by the NIH for
patents arising from federal funding).3 19 As an illustration, in 1996 Congress
granted medical practitioners statutory immunity from liability for infring-
ing patents on medical methods while performing any "medical activity."320
Importantly, the statute merely shields a class of potential defendants from
liability and does not in any way restrict PSM. This example demonstrates
the benefits of a multi-institutional approach to tailoring. Congress was able
to address the concerns of a narrow interest group (doctors seeking protec-
tion from infringement liability) without radically transforming the patent
doctrine and thereby creating far-reaching unintended consequences for the
biomedical industry.
The Federal Circuit should apply the proposed model to all claims that
raise normative questions of patent scope. Medical and surgical procedures
arguably best track cumulative-innovation theory, since the pioneering pro-
cedure typically is refined with follow-on improvements as physicians gain
experience with the technique in the course of treating patients. This argues
against broad upstream patents and perhaps against any patents at all in this
context. Possible cases in which patents on medical and surgical procedures
may be desirable are those involving breakthrough techniques that require a
substantial investment of time and money to develop. Nuanced contextual
analysis could elicit the data necessary to confirm these empirical intuitions.
An analogous approach could be taken to the patentability of inventions in
other technological fields (such as those involving software or business
methods). Software research, like medical research, is characterized by sub-
stantial government funding and cumulative innovation. The software
industry also manifests network effects and possesses a wide range of non-
patent means of appropriating value.321 in many cases, inventors of novel
business methods may be able to rely on trade secret protection and/or first-
319. Kane, supra note 241 (noting possible field-wide solutions); see also SACGHS
REPORT, supra note 311, at 93-96 (recommending the following statutory changes: (1) The
creation of an exemption from liability for infringement of patent claims on genes for anyone
"making, using, ordering, offering for sale, or selling" a test developed under the patent for
patient care purposes; and (2) "[T]he creation of an exemption from patent infringement lia-
bility for those who use patent-protected genes in the pursuit of research").
320. 35 U.S.C. § 287(c) (2011).
321. Menell, supra note 220, at 495.
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mover advantages to profit from their innovations. 322 The Federal Circuit
should explicitly incorporate such practical considerations into its applica-
tion of the PSM doctrine.
CONCLUSION
Since its inception, the Federal Circuit has framed its primary objective
as maintaining predictability and stability in the patent law. In furtherance of
this goal, the court formulates seemingly bright-line rules but then contorts
them to reach intuitively desirable outcomes in specific cases. By adopting
this strategy of "feigned formalism," the Federal Circuit creates doctrinal
confusion and perpetuates uncertainty about patent law's impact on incen-
tives to create, develop, and commercialize innovative technologies.
Heightened Supreme Court scrutiny compels the Federal Circuit to
rethink its patent jurisprudence. This Article argues that the court should use
the PSM doctrine as an explicit policy lever to candidly confront the
fundamental factual questions driving disagreements about the extent to
which an inventor should be able to assert patent rights in after-arising
technologies. Expressly pragmatic adjudication would compel interested
parties to directly address empirical uncertainty about patents' practical
effects. This approach promises to further the patent law's utilitarian
purpose by striking a socially desirable balance between legal stability and
flexibility.
322. See, e.g., Levin et al., supra note 229; Burk & Lemley, supra note 3, at 1618
(discussing various first mover advantages, such as branding and network effects).
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